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CHAPTER 1  
 
INTRODUCTION 
 
1. 1 NEUTROPHILS 
 
1.1.1 Origin and main characteristics 
 
Neutrophils (also called polymorphonuclear leukocytes, PMN) are the most abundant 
white blood cells in humans (1). Humans and mice differ in the number of circulating 
neutrophils: in humans, 50–70% of circulating leukocytes are neutrophils, as 
compared to only a 10–25% in mice (2, 3). PMN are generated in the bone marrow at 
a rate of 10
11
 cells/day (4). In the circulation, mature neutrophils have an average 
diameter of 7–10 μm, their nucleus is segmented and their cytoplasm is enriched with 
granules and secretory vesicles (5).  
PMNs were always considered short-lived cells with a half-life in the circulation of 
approximately 1.5 and 8 hours in mice and humans, respectively (6, 7). Nevertheless, 
a recent study challenged this concept, proposing that under basal conditions the 
average circulatory lifespan of neutrophils might rise up to 12.5 hours for mouse cells 
and 5.4 days for human neutrophils (6).  
 
During inflammation, neutrophils become activated by cytokines, growth factors, and 
bacterial products (8, 9) and their longevity increases by several fold. This process 
ensures a longer presence of primed neutrophils at the site of inflammation (8,10). A 
longer lifespan may allow neutrophils to carry out more complex activities in a tissue, 
such as contributing to the resolution of inflammation or shaping adaptive immune 
responses, but their persistence in tissues may lead to bystander cell injury.  
Data from experimental and clinical settings show that the re-localization of 
neutrophils to the site of inflammation is crucial for clearance of infections, although 
an excessive infiltration and activation of neutrophils at the site of tissue damage can 
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cause chronic inflammation, limit injury repair and lead to loss of organ function 
(11,12). Indeed, a marked decrease in neutrophil numbers in the blood leads to severe 
immunodeficiency in humans (13,14). Thus, the recruitment and the functions of 
neutrophils are tightly controlled. 
In most tissues, the leukocyte recruitment cascade involves the following commonly 
recognized steps: tethering, rolling, adhesion, crawling and, finally, transmigration, as 
shown in Figure 1. Neutrophil recruitment is initiated by changes on the surface of 
endothelium, as a result of stimulation by inflammatory mediators (including 
histamine and cytokines) released by tissue-resident sentinel leukocytes upon contact 
with pathogens (15-17). Once neutrophils are recruited, specific molecule expression 
is modulated in order to ensure rolling (selectins) adhesion and migration (integrins) 
through the endothelium. 
 
 
 
 
 
 
 
 
 
Fig.1 Leukocyte extravasation. This process concerns the movement of 
leukocytes out of the circulatory system and towards the site of tissue damage or 
infection. The different steps of the adhesion cascade are capture, rolling, slow 
rolling, firm adhesion, and transmigration. Each of these steps appears to be 
necessary for effective leukocyte recruitment (W. A. Muller, 2013). 
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1.1.2 Neutrophil functional roles 
 
Neutrophils play a well-established role in host defense against pathogens (18, 19). 
PMNs detect the presence of pathogens through germ line-encoded receptors that 
recognize microbe-associated molecular patterns. In vertebrates, the most 
characterized receptors are Toll-like receptors (TLRs). Ten human TLRs have been 
identified which enable responses to a range of pathogen-associated molecules 
including LPS (TLR4), lipoproteins and peptidoglycans (TLR2 in combination with 
TLR1 or TLR6), flagellin (TLR5), double-stranded (viral) RNA (TLR3), and 
bacterial DNA (CpG motifs, TLR9). In addition, TLR4 recognizes not only LPS but 
also non-infective inflammatory stimuli such as heat shock protein 60 (HSP60) and 
fibrinogen peptides (20-23).  
 
An increasing number of studies have documented that TLR-induced cytokine 
expression by neutrophils can be influenced, either positively or negatively, by 
immunomodulating factors such as IFNγ (24, 25) and IL-10 (26), respectively.  
 
Recently it has been shown that melanoma patients possess a higher number of 
circulating neutrophils that secrete IL-10 after recognition of serum amyloid A-1 
(SAA-1), one of the first and most abundant proteins secreted during the 
physiological response to infections and injuries. In this work it was suggested that 
this process, together with the functional interaction with immune cell subsets such as 
iNKT cells, might directly control the plasticity of neutrophil differentiation (27). 
 
Once detected, PMNs target microorganisms through a number of processes 
including (Figure 2):  
i) degranulation through the release of granular antimicrobial peptides such as 
myeloperoxidase (MPO), neutrophil elastase and matrix metalloproteinases (MMPs);  
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ii) phagocytosis and degradation via synthesis of reactive oxygen species (ROS) 
inside phagolysosomes  
iii) microbial trapping by extrusion of a meshwork of chromatin bound to granular 
peptides termed neutrophil extracellular traps (NETs) (28). 
 
Neutrophils contain in their cytoplasm granules necessary to perform their functions. 
PMN granules have been classified into three types: azurophilic (primary) granules, 
specific (secondary) granules and gelatinase (tertiary) granules (29). Azurophilic 
granules can be distinguished from the other types by their uptake of basic dye azure 
A, owing to their acid mucopolysaccharide content, and contain myeloperoxidase 
(MPO), azurocidin, bacterial permeability-increasing protein, cathepsin G, defensins, 
elastase and human neutrophil peptides. Secondary granules contain cathelicidin 
antibacterial peptide (also known as antibacterial peptide LL-37), lactoferrin and 
neutrophil gelatinase-associated lipocalin. Tertiary granules contain peptidoglycan 
recognition proteins. Lysozyme is present in all three types of granules. Together 
these antimicrobial granular proteins have an important role in the activation of 
innate and adaptive immunity (30). 
 
Neutrophils are also able to synthetize reactive oxygen species (ROS), that is a 
collective term that describes the chemical species that are formed upon incomplete 
reduction of oxygen and includes the superoxide anion (O2
–
), hydrogen peroxide 
(H2O2) and and hypochlorous acid (HOCl) (31). 
 
ROS are generated as by-products of cellular metabolism through the electron 
transport chain (ETC) in mitochondria as well as via the cytochrome P450. The other 
major source in which ROS are not produced as by-products, are the NADPH 
oxidases that are present in a variety of cells, especially the professional phagocytes 
and endothelial cells (32), which are central to the genesis of the inflammatory 
response (33). 
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In 2004, the group of Brinkmann and Zychlinsky described how after stimulation 
with interleukin-8 (IL-8), phorbol myristate acetate (PMA), or lipopolysaccharide 
(LPS), neutrophils formed previously unknown NET-like structures called neutrophil 
extracellular traps (NETs) (34).  
These structures were composed by nuclear chromatin, associated mainly with 
nuclear histones and many granular antimicrobial proteins, and with cytoplasmic 
proteins (35).  Moreover, NETs are also generated and released during a distinct 
process of cell death called NETosis (Fig.3) (36). In addition to triggering innate 
immune responses, neutrophils regulate the adaptive immune response (37) and 
NETosis also contributes to the activation of the immune system during inflammation 
(38, 39).  Neutrophils can interact with B cells (40, 41), T cells (42, 43) and antigen 
presenting cells in lymphoid organs (44, 45). The cytokines, proteases and other 
factors contained in PMN cytoplasmic granules and released during PMNs functional 
Fig. 2 Neutrophils killing mechanisms. Neutrophils kill pathogens through 
intracellular mechanism such as phagocytosis, and extracellular  mechanisms such 
as ROS production and NETosis (Segal A., 2005; Zawrotniak M., 2003). 
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activation, can act by directly regulating the activity of the adaptive immune 
response, including both B cell and T cell activation. The type of response, the 
cytokine milieu and the cell types encountered during the course of the immune 
activation contribute to shaping the phenotype and function of neutrophils, similarly 
to what is observed for macrophages (46-50). 
 
 
 
 
 
         
 
 
 
 
 
 
 
 
 
 
Fig.3 NETs Formation. Neutrophils kill pathogens through the formation of extracellular 
fibers named NETs, primarily composed of proteins from azurophilic granules (neutrophil 
elastase, cathepsin G and myeloperoxidase) and DNA of the same cells, which bind 
pathogens (Zawrotniak M., 2003) 
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1.2 Inflammatory Bowel Diseases  
 
1.2.1 Epidemiology 
 
Inflammatory bowel diseases (IBD) are a chronic, relapsing, inflammatory disorders 
of the gastrointestinal tract and include ulcerative colitis (UC) and Crohn’s disease 
(CD), which differ in the pathology and clinical characteristics. These pathologies are 
characterized by abdominal pain, fever, chronic diarrhea, and rectal bleeding due to 
ulceration of the inner lining of the colon and/or rectum, which can be accompanied 
by complications such as fistulation, stenosis, and abscesses in CD and megacolon in 
UC. Currently, the etiology and pathogenesis of IBD are still poorly understood. It is 
widely accepted that IBD arise in genetically predisposed individuals as the result of 
an exaggerated reaction of gut-associated lymphoid tissue (GALT) to bacterially-
derived antigens (51). IBD arise in young adults and manifest a chronic course. The 
incidence of IBD varies according to geographic location, but in the last decade it has 
been observed a general increase worldwide.  Since the middle of the twentieth 
century, the incidence of ulcerative colitis and Crohn’s disease has increased in the 
Western world, including North America, Europe, Australia and New Zealand. 
Currently, the prevalence of IBD in the Western world is up to 0.5% of the general 
population (52) (Fig.4). 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Historical timelines of CD and UC diseases throughout the world 
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Over the past few decades, newly industrialized countries in Asia, South America and 
the Middle East have documented the emergence of IBD (53-58). The incidence of 
IBD in these newly industrialized countries is still considerably lower than that in the 
Western world, but IBD is considered a global disease (59), as shown in Figure 5. 
 
 
 
 
 
 
A variety of environmental and behavioural factors are linked to IBD pathogenesis, 
including diet, smoking, stress, sleep patterns, hygiene, and antibiotic use (60). 
Considerable advances have been made in recent years in the understanding of the 
role of the genes, the intestinal immune system, and the gut microbiome in the 
pathogenesis of CD and UC (61, 62).  
 
 
 
Fig. 5. The global  prevalence of  IBD in 2015 
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1.2.2 Genetics in IBD 
 
The association of IBD susceptibility genes with bacteria has recently been 
highlighted. Epidemiological studies of IBD have revealed its polygenic and 
multifactorial nature (63, 64). Genetic analyses of IBD patients have identified over 
200 loci associated with UC or CD risk (65-67).   
 
Interestingly, several of the identified risk loci play also significant roles in 
determining susceptibility to infections and to the host-microbial response, further 
strengthening the interaction between the gut microbiome and the intestinal immune 
system in the development of IBD. Risk genes included nod2 in CD (69, 70), il-10, 
il23r, and atg16l1 (71) (Fig.6).  
 
A recent meta-analysis of GWAS reported 163 genetic loci associated with IBD (72). 
Of these, 110 loci were shared by UC and CD, while 30 and 23 loci were specific to 
CD and UC, respectively (73). However, candidate genes that in patients functionally 
contribute to disease susceptibility have not been confirmed by GWAS, underlying 
the complexity of these diseases.  
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Fig.6 During homeostasis beneficial subsets of commensal bacteria tend to have anti-inflammatory 
activities. In inflammatory bowel disease (IBD) a combination of genetic factors (for example, 
mutations in nucleotide-binding oligomerization domain 2 (Nod2), autophagy-related gene 16-like 1 
(Atg16l1) and interleukin-23 receptor (Il23r) and environmental factors (such as infection, stress and 
diet) result in dysbiosis (Ballester V., 2004). 
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1.2.3 The role of the gut microbiota in IBD 
 
The gut is a complex environment composed of immune cells, epithelial cells, 
stromal cells and the intestinal microflora. The host provides the gut bacteria with a 
nutrient-rich environment and bacteria, in turn, contribute to the host homeostasis 
through short-chain fatty acids and essential vitamins production. This mutual 
relationship between the host and the gut bacteria is called symbiosis. Recent 
advancement of next-generation sequencing techniques has enabled culture-
independent analysis of the gut microbiota, revealing that an altered balance of the 
gut microbiota constituents, rather than specific pathogens, is involved in the 
pathophysiology of several diseases. This shift in the balance of the gut microbiota 
composition is referred to as dysbiosis. The normal gut microbiome comprises 100 
trillion diverse microbes, mostly bacteria, with at least 160 species in each individual 
(74).  
 
More than 90% of the human gut microbiota is composed of four major phyla. The 
Firmicutes (49-76%) and Bacteroidetes (16–23%) phyla dominate, followed to a 
much less extent by the Proteobacteria and Actinobacteria phyla (75, 76). The 
Firmicutes phylum is mainly composed by the Clostridium XIV and IV groups.  
 
IBD patients show a marked dysbiosis as compared to healthy individuals. The most 
well defined change that has been noted in patients with IBD is the reduced 
abundance of the phyla Firmicutes (77-79). Amongst the Firmicutes, the reduced 
presence of Faecalibacterium prausnitzii has been well documented in patients with 
CD as opposed to controls (80-83). Additionally, it has been suggested that there may 
be spatial reorganization of the Bacteroides species in patients with IBD, with 
Bacteroides fragilis being responsible for a greater proportion of the biofilm mass in 
patients with IBD compared to controls, due to increased adherence (84). 
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Most of the known pathogenic bacteria in humans belong to the phylum 
Proteobacteria, which have been increasingly found to have a key role in IBD (85). 
Increased concentrations of Escherichia coli including pathogenic variants have been 
documented in ileal CD (86, 87).  
 
This interesting shift within the gut microbiome with a decrease in obligate anaerobes 
of the phylum Firmicutes and an increase in facultative anaerobes of Proteobacteria 
has given rise to a putative “oxygen” hypothesis wherein disruption in anaerobiosis 
points to a role for oxygen in intestinal dysbiosis (88). The ileal CD patients were 
found to have alterations in bacterial carbohydrate metabolism, bacterial-host 
interactions, as well as human host-secreted enzymes (89). 
There are several specific bacteria that are associated with IBD. Mycobacterium 
avium spp. paratuberculosis (MAP) causes chronic granulomatous ileitis (Johne’s 
disease) in cattle and sheep, which shares some pathological features with CD (90). 
Adhesive-invasive E. coli (AIEC), which can adhere to and invade the intestinal 
epithelial cells, colonize the ileal mucosa of CD (91). AIEC also replicate in 
macrophages and stimulate TNFα production from macrophages. It was observed that 
Fusobacterium varium attaches to inflamed regions in UC and invades the mucosa at 
ulcers (92). F. varium produces butyrate, and rectal administration of butyrate has 
been shown to cause mucosal damage in mice (93). 
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1.2.4 Neutrophils and IBD 
 
In IBD patients it is observed a robust inflammatory response associated with 
mucosal injury, increased epithelial permeability and invasion of commensal bacteria 
into the subepithelial space or lamina propria (94).  Circulating neutrophils sense the 
chemoattractant gradient originated by the inflammatory responses in the gut and 
traverse the vascular endothelium to reach the intestinal lamina propria. Nevertheless, 
once recruited to the lamina propria, the relative contribution of PMN to the 
pathogenesis of IBD is controversial. Some studies describe a beneficial role by 
neutrophils in resolving intestinal inflammation, yet others report pathological 
contribution. 
 
During intestinal inflammation, neutrophils secrete significant amounts of pro-
inflammatory cytokines such as CXCL8 and IL-17 (95) in response to IL-23 and IL-6 
(96), which has been widely implicated in pathological intestinal inflammation (97). 
Another potential contribution of PMN to pathological immune cell activation 
includes the ability to acquire antigen-presenting function during colitis, an event 
previously reported also during rheumatoid arthritis (98). PMN isolated from 
inflamed colon in a murine model of adoptive transfer of CD4+ T cells were reported 
to express major histocompatibility complex-II and CD86, usually present on 
antigen-presenting cells such as macrophages or dendritic cells but not on PMN. Such 
neutrophils were capable of inducing in vitro CD4+ T cell activation in a major 
histocompatibility complex-II- and antigen-dependent manner (99). Although these 
findings have not been confirmed in other murine colitis models or in human disease, 
it is intriguing that PMN might contribute to the pathogenesis of colitis by activating 
T cells.  
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Finally, during the inflammatory response, neutrophils are capable to secrete anti-
inflammatory cytokines, including interleukin (IL)-10 (100-102). IL-10 down-
regulates major histocompatibility complex-II (MHC class II) expression (103) and 
the expression of the co-stimulatory ligands CD80/CD86 (B7-1, B7-2) in monocytes, 
macrophages and dendritic cells (104). Moreover PMNs contribute to the recruitment 
of immune cells that facilitate mucosal healing by secreting chemokines and by 
releasing mediators necessary for the resolution of inflammation (105). 
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1.3 Colorectal Cancer (CRC) 
 
1.3.1 Epidemiology and Risk Factors 
 
Colorectal cancer (CRC) is an important public health problem with nearly one 
million new cases diagnosed world-wide each year and half a million deaths. It 
accounts for over 9% of all cancer incidence and it is the third most common cancer 
worldwide and the fourth most common cause of death. CRC affects men and women 
almost equally with a slight male predominance for rectal cancer (108), and the 
highest incidence rates occur in Australia, New Zealand, Canada, the United States, 
and parts of Europe. The countries with the lowest risk include China, India, and 
parts of Africa and South America (106, 107). 
 
Several risk factors are associated with the incidence of colorectal cancer. Those that 
an individual cannot control include age and hereditary factors. In addition, a 
substantial number of environmental and lifestyle risk factors may play an important 
role in the development of colorectal cancer, that include physical inactivity, obesity, 
high consumption of red processed meat, smoking, and moderate-to-heavy alcohol 
consumption (109). 
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1.3.2 IBD- associated colorectal cancer  
 
Patients with inflammatory bowel diseases (IBD) have an increased risk of 
developing colorectal cancer, even though no genetic correlation has been identified 
yet. The mortality rate of patients suffering from IBD who have been diagnosed with 
colorectal cancer is higher than that occurring for sporadic colorectal cancer. The risk 
of developing colorectal cancer in patients with IBD has been reported to be between 
7% and 14% in multiple studies after a disease duration of 25 years (110, 111). Some 
studies have reported the risk to be as high as 30% in patients who have had IBD for 
greater than 35 years (112, 113). 
 
1.3.3 Bacteria and Cancer 
 
Several human studies have demonstrated a link between the gut microbiota 
composition and CRC development. Initial studies associated abundance of 
Bacteroides and Bifidobacteria with increased risk of developing colon polyps, 
whereas Lactobacillus and Eubacterium aerofaciens presence were shown to be 
protective (116). Other studies also reported an association between the abundance of 
Escherichia Coli and Colorectal Adenomas and Cancer development (117) and 
between an higher abundance of hydrogen sulfide (H2S) producing bacteria and 
increased risk of colon cancer (118). More recent studies that took advantage of high-
throughput molecular sequencing methods, revealed changes in fecal microbiota 
composition in CRC subjects as compared to healthy individuals (119, 120). Patients 
with colorectal adenomas showed a concomitant reduced abundance of Clostridia, 
Roseburia, Eubacteria spp., and other butyrate-producing bacteria in fecal samples of 
adenoma subjects compared with healthy controls (121). Lactobacillus and 
Bifidobacterium, benefit the host through anti-inflammatory and anti-tumorigenic 
properties, as well as through pathogen exclusion (122-124). It was also demonstrated 
an overabundance of Fusobacterium Nucleatum within the tumor site compared with 
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normal tissue (125). Other specific strains of bacteria have been classified as 
cancerogenic pathogens, such as Streptococcus bovis, H. pylori, and Enterococcus 
faecalis (126,176,177).  
Most of the disease-promoting and pro-carcinogenic effects of these pathobionts 
depend on virulence factors (127), in particular on afa and eae adhesins for E.coli 
(128, 129) FadA virulence factor for F. nucleatum (130) or, CagA or VacA for H. 
pylori (131, 132); B. fragilis can also exert a virulent potential through the production 
of the metalloprotease toxin BFT. The so called enterotoxigenic B. fragilis, that 
comprises a relatively small proportion of fecal microbiota (approximately 0.5%-
1%), is more prevalent in late-stage CRC, suggesting a possible role of BFT in CRC 
promotion and progression (133) (Fig.7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Possible mechanisms by which the gut bacterial microbiota 
participates in colorectal carcinogenesis (Gagnière J, 2016). 
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1.3.4 Neutrophils and Cancer 
 
 
In recent years, accumulating data suggest important and significant roles for 
neutrophils in tumor biology (134, 135), given that they have been found in vivo in 
close association with tumor cells and within tumour vasculature (136). However, the 
exact role of neutrophils in the tumor microenvironment is controversial. Many 
patients with advanced cancer show elevated blood neutrophilia (137), which has 
been associated with poorer prognosis in many types of cancers, including 
bronchoalveolar carcinoma (138), metastatic melanoma (137) and renal carcinoma 
(139). On the contrary, the neutrophil- to- lymphocyte ratio has been introduced as a 
prognostic factor in many tumor types, including colorectal cancer and non-small cell 
lung cancer (140). An elevated neutrophil-to-lymphocyte ratio (NLR) of the 
peripheral blood, reflecting the systemic immune response, has been correlated with 
poor clinical outcome in patients with advanced CRC (141). CRC patients with 
elevated NLR (>5) have tumors characterised by aggressive biology and a distinctive 
expression profile of cytokines involved in angiogenesis, inflammation, and 
regulation of the EGF axis (142). Neutrophils can make up a significant portion of the 
inflammatory cell infiltrate in many models of cancer, and it has been shown that 
tumor cells themselves mediate neutrophil recruitment to the tumour (143). 
When neutrophils traffic into tumors, they are referred to as Tumor-associated 
neutrophils (TAN).  
 
 
 
 
 
 
 
 
19 
 
1.3.5 Tumor infiltrating-cells: MDSC, TAMs and TANs  
 
The tumor microenvironment includes tumor cells, the surrounding blood vessels, the 
extracellular matrix, the immune infiltrate and, in intestinal tumors, also commensal 
bacteria. Among infiltrating immune cells, an important role is played by myeloid 
derived suppressor cells (MDSC), a heterogeneous group of myeloid cells 
characterized by potent immune-suppressive activity. In mice, they are generally 
characterized as Gr-1
+
CD11b
+
 cells. Under physiological conditions, immature 
myeloid cells with this phenotype are present in bone marrow and in the spleen, and 
lack immune-suppressive activity. In contrast, in a tumor-bearing host, there is a 
dramatic expansion of cells with the same phenotype and immune-suppressive 
activity in various tissues (144).  
In recent years, in tumor-bearing mice, two major groups of cells with phenotypic 
and functional characteristics of MDSCs were identified: cells with morphology and 
phenotype typical for monocytes were called M-MDSC (CD11b
+
Ly6C
high
Ly6G
–
), 
and cells with morphology and phenotype typical for granulocytes were named G-
MDSC (CD11b
+
Ly6C
low
Ly6G
+
)  (145-147). In humans, MDSC are typically defined 
as CD11b
+
CD33
+
CD34
+
 CD14
–
HLA-DR
–
, with a variable expression of CD15 (148). 
It has been previously proposed that MDSC entering the tumor microenvironment 
can differentiate into tumor-associated macrophages (TAM) or tumor-associated 
neutrophils (TAN) in mice, and can promote tumor growth by favouring 
angiogenesis, hypoxia and immunosuppression  (149, 150); in humans the 
relationship between TAMs, TANs and MDSC has not been fully clarified. 
 
TAMs were firstly described in the early 1980s (151, 152). Analogously to the old T 
helper cell dichotomy, Th1 and Th2, macrophages exist in two distinct polarized 
states: one is the classically activated state (M1) and the other is the alternatively 
activated state. (M2). M1 macrophages possess antitumor activity, whereas M2 
macrophages promote tumor invasion and metastasis (153). The M1 activation is 
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induced by intracellular pathogens, bacterial cell wall components, lipoproteins, and 
cytokines such as interferon gamma (IFN-y) and tumor necrosis factor alpha (TNF-
α). Activated M1 macrophages secrete inflammatory cytokine and produce nitric 
oxide (NO), resulting in an effective pathogen killing function (154).  
 
The M2 activation is induced by fungal cells, parasites, immune complexes, 
complements, apoptotic cells, macrophage colony stimulating factor (MCSF), 
interleukin-4 (IL-4), IL-13, IL-10 and tumor growth factor beta (TGF-β) (155). The 
M2 macrophages have high phagocytic capacity, produce extracellular matrix 
components, angiogenic and chemotactic factors, and IL-10 (156, 157). 
 
Those TAMs demonstrating enhanced expression of CD163 (hemoglobin scavenger 
receptor), CD204 (class A macrophage scavenger receptor), CD206 (mannose 
receptor, C type 1), stabilin-1, arginase-1, and accelerated production of IL-10, 
VEGF, PGE2, and MMP9, generally show characteristics of M2 macrophages (158-
160) (Fig. 8). 
 
 
 
 
 
 
Fig. 8 Changes in macrophage phenotype. Plasticity of macrophage, 
when infiltrating tissue (Quatromoni JG. et al., 2012) 
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The critical functions of tumor-associated neutrophils (TANs) have only recently 
become appreciated. Surface markers used for the identification of neutrophils in 
tumor tissues include CD66b and CD15 (161). CD66b is GPI- anchored glycoprotein 
of the carcinoembryonic antigen (CEA) family and is located in the specific granules 
(162) and is associated to the aggregate formation of human neutrophils (163, 164).  
 
Murine neutrophils that remained longer in the circulation were shown to express 
reduced levels of CD62L (also known as L-selectin), while expression of CXCR4 
increased over time (165). In human lung tumor, compared with blood neutrophils, 
TANs displayed an activated phenotype (CD62L
low
CD54
high
) with a distinct 
repertoire of chemokine receptors that included CCR5, CCR7, CXCR3, and CXCR4.  
 
Functionally, both TANs and neutrophils isolated from distant non-malignant lung 
tissue were able to stimulate T cell proliferation and IFN-γ release. Cross-talk 
between TANs and activated T cells led to substantial upregulation of CD54, CD86, 
OX40L, and 4-1BBL costimulatory molecules on the neutrophil surface. Recent 
studies have demonstrated also the expression of co-inhibitory molecules, such as 
PD-L1, in neutrophils following in vitro exposure to cytokines or after stimulation by 
LPS or other toll-like receptor ligands (TLRs) (166, 167).  
 
PD-L1 expression on neutrophils was also increased in vivo in patients with active 
tuberculosis (TB) or HIV infection while it was decreased in patients who received 
anti-TB therapy or anti-viral treatment (168, 169). Subsets of neutrophils have also 
been defined by surface receptor expression and density (low-density neutrophils 
versus high- or normal-density neutrophils) (170).  
 
For example, CXCR4 expression is increased in aged or senescent neutrophils and is 
associated with neutrophil trafficking to the bone marrow. Other changes in the 
expression of surface proteins on neutrophils have been described, including 
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intercellular adhesion molecule 1 (ICAM1) expression associated with systemic 
inflammation and reverse migration (171). 
 
Similarly to TAM, also TANs appear to have dichotomous pro-tumorigenic and anti-
tumorigenic effects (172, 173).  Tumor-associated neutrophils can be designated as 
N1 (anti-tumorigenic and pro-inflammatory) and N2 (pro-tumorigenic and 
immunosuppressive). N2 neutrophils are characterized by high expression of CXC-
chemokine receptor 4 (CXCR4), vascular endothelial growth factor (VEGF) and 
matrix metalloproteinase 9 (MMP9) and are induced in the presence of high levels of 
transforming growth factor-β (TGFβ). By contrast, N1 neutrophils expressing pro-
inflammatory cytokines and chemokines, can kill cancer cells and are induced by 
inhibition of TGFβ signalling (Fig. 9) (174). An increase of IFN-β can also alter the 
phenotype of TANs to a more anti-tumorigenic phenotype (N1) (175). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 Plasticity of neutrophils . Neutrophils are driven by transforming growth factor-β 
(TGFβ) to acquire a polarized, pro-tumoural N2 phenotype (characterized by high levels of 
arginase expression). By contrast, inhibition of TGFβ promotes a reprogramming of 
neutrophils to an N1 phenotype. This is associated with higher cytotoxic activity, higher 
capacity to generate hydrogen peroxide, higher expression of tumour necrosis factor (TNF) 
and intercellular adhesion molecule 1 (ICAM1), and lower expression of arginase (Perobelli 
SM et al., 2015). 
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CHAPTER 2 
 
MATERIALS AND METHODS  
 
2.1 PATIENTS 
 
A total of 33 patients (17 with CD, 6 with UC and 10 with CRC) were enrolled in this 
study. IBD patients were classified according to disease, age, and concomitant 
therapies (mesalazine = 5’-ASA, azathioprine=AZA and steroids) that include 
biological drugs (Adalimumab=ADA). CRC patients were classified according to 
age, staging of tumor and concomitant therapies; as controls, a total of 16 patients (6 
patients with diverticulitis and 10 non-CRC patients) were enrolled. The intestinal 
segments resected and clinical characteristics of the patients and controls are 
summarized in Table 1, Table 2, Table 3 and Table 4. 
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TABLE 1.  Baseline characteristics of IBD patients 
SUBJECTS SEX DISEASE AGE 
INTESTINAL 
SEGMENTS 
THERAPY 
1 F CD 48 Colon - 
2 M CD 41 Colon - 
3 F CD 49 Colon - 
4 F CD 47 Colon - 
5 F CD 34 Ileum - 
6 M CD 29 Colon - 
7 F CD 76 Colon - 
8 M CD 51 Colon - 
9 F CD 45 Ileum - 
10 F CD 52 Colon - 
11 M CD 40 Colon - 
12 M CD 35 Ileum AZA 
13 F CD 47 Ileum AZA 
14 F CD 50 Ileum AZA 
15 F CD 38 Colon 5’-ASA 
16 M CD 57 Colon 5’-ASA 
17 F UC 18 Colon - 
18 F UC 43 Colon - 
19 M UC 48 Colon - 
20 M UC 50 Colon 5'-ASA 
21 F UC 46 Colon 5'-ASA 
22 M UC 41 Colon steroids 
     BIOLOGICAL 
DRUGS 23 F CD 49 Colon ADA 
  
AZA= azathioprine; 5’-ASA= 5-Aminosalicylic acid (mesalazine); ADA=Adalimumab 
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TABLE 2. Baseline characteristics of CRC patients 
SUBJECTS DISEASE AGE 
TNM 
STAGING 
THERAPY 
1 CRC (IA) 84 I - 
2 CRC (IA) 69 I - 
3 CRC (IA) 82 I - 
4 CRC (IA) 74 IIa steroids 
5 CRC (IA) 71 IIa steroids 
6 CRC (IA) 81 IIa steroids 
7 CRC (IA) 76 IIa steroids 
8 CRC (IA) 62 IIIb steroids 
9 CRC (IA) 64 IIIb - 
10 CRC (IA) 67 IIIb - 
CRC= Colorectal cancer; IA= intra-tumoral area;  
TABLE 3. Baseline characteristics of healthy controls (blood) 
SUBJECTS DISEASE AGE THERAPY 
1 Diverticulitis 81 - 
2 Diverticulitis 81 - 
3 Diverticulitis 44 - 
4 Diverticulitis 74 - 
5 Diverticulitis 63 - 
6 Diverticulitis 68 - 
    
TABLE 4. Baseline characteristics of healthy controls (tissue) 
SUBJECTS DISEASE AGE THERAPY 
1 Non-CRC 84 - 
2 Non-CRC 69 - 
3 Non-CRC 82 - 
4 Non-CRC 74 - 
5 Non-CRC 71 - 
6 Non-CRC 81 - 
7 Non-CRC 76 - 
8 Non-CRC 62 - 
9 Non-CRC 64 - 
10 Non-CRC 67  
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2.2 ISOLATION OF HUMAN NEUTROPHILS 
 
To perform phenotypic and functional characterisation of circulating and tissue 
infiltrating human neutrophils, we set up two protocols of purification from 
peripheral blood and from intestinal specimens of IBD and CRC patients and of 
healthy individuals.  
 
Peripheral blood samples and surgical specimens were received from Fondazione 
IRCCS Ca' Granda - Ospedale Maggiore Policlinico  (Milan, Italy).  
 
2.2.1 Isolation of human PMN from blood 
 
10 ml of peripheral blood of CTR and IBD/CRC patients was mixed with an equal 
volume of dextran/saline solution (3% dextran from Leuconostoc spp (Sigma) in 
0,9% NaCl and incubated in upright position for 20 minutes at room temperature.  
 
Dextran promotes erythrocyte rouleaux formation, which results in differential 
sedimentation of RBC and the formation of a leukocyte-rich, RBC-poor plasma layer 
above the sedimented RBC. The upper layer (leukocyte-rich plasma), was aspirated 
and was centrifuged for 10 min at 1000 rpm, 5°C. Cell pellet was resuspended in a 
volume of 0,9% NaCl equal to the starting volume of blood and 15 ml Ficoll-Paque
TM
 
PLUS (GE Healthcare) was statified beneath the cell suspension using a pipet 
centrifuged for 40 minutes at 1400 rpm, 20 °C, with no brake. After this stratification, 
the top (saline) layer was aspirated,as well as the Ficoll-Pacque layer, leaving the 
neutrophil/RBC layer.  
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To remove residual RBC, cells were subjected to hypotonic lysis by resuspending 
neutrophil/RBC pellet in 20 ml of cold 0,2% NaCl for exactly 30 seconds. At the end 
of this period, the isotonicity was restored by adding 20 ml of ice-cold 1,6% NaCl. 
This hypotonic lysis is based on the high sensitivity of RBC to hypotonicity, in 
comparison with neutrophils. However, the 30 seconds limit must be carefully 
observed since a more prolonged period of hypotonicity will result in neutrophil 
damage.  After hypotonic lysis, cells were centrifuged for 6 minutes at 1000 rpm, 
5°C, and the supernatant was discarded. Cells was resuspended RPMI (Fig. 10).  
 
 
 
 
 
 
 
Figure 10. Schematic representation of isolation of human neutrophils from blood. Peripheral 
blood of CRC patients, IBD patients and healthy individuals, was diluted with 3% Dextran to remove 
RBC cells. Human neutrophils were separated from other blood cells by Ficoll.  
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2.2.2 Isolation of human PMN from Gut Tissue 
 
To isolate neutrophils from intestinal surgical specimens, we firstly resected the 
tissue and separated the mucosa from the submucosa with forceps and surgical 
scissors. Gut mucosa was treated with DTT (Sigma Aldrich) solution for 15 min RT  
under slow rotation. Pretreatment with dithiothreitol (DTT) is necessary to dissolve 
intestinal mucus. After three washes with HBSS supplemented with antibiotics for 5 
min, the mucosa was minced in small pieces with scalpel and knife and was 
incubated three times with EDTA solution for 50 min RT under slow rotation. EDTA 
was used to eliminate the epithelial cell layer. After three washes with HBSS 
supplemented with antibiotics for 5 min, the tissue was incubated in a digestion 
solution containing collagenase D (Roche) dissolved in RPMI 1640 medium sterile 
filtered (Gibco, Life Technologies) supplemented with 2% Penicillin/Streptomycin 
(Gibco, Life Technology) and Gentamycin (Roche, Ci= 40mg/ml) and 10% FBS 
(Gibco, life Technologies) at 37°C for 5 h in 5% CO2 under slow rotation. Cells were 
filtered with a 100 µm cell strainer and then centrifuged at 1930 for 10 min at RT. 
The cells were purified using a Percoll gradient (100%, 60%, 40% and 30%) (Sigma) 
followed by centrifugation at 1930 RPM without accelerator nor brake for 30' RT to 
avoid cells mixed. Once collected, the cells were washed two times in PBS 
supplemented with 2% Penicillin/Streptomycin (Gibco, Life Technology) and 
Gentamycin (Roche, Ci= 40mg/ml), and the cells were counted using Burker 
counting chumber (Fig. 11). 
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2.2.3 Cell culture 
 
Human neutrophils were cultured in RPMI 1640 medium sterile filtered (Gibco, Life 
Technologies) supplemented with 10% Fetal Bovine Serum (FBS) and 2% 
Penicillin/Streptomycin (Gibco, Life Technologies) and put in a humified incubator 
at 37°C with 5% CO2 
 
 
 
Figure 11. Schematic representation of isolation of human neutrophils gut tissue. Schematic 
representation of neutrophils isolation from human intestinal tissue. 
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2.3 FLOW CYTOMETRY 
 
2.3.1 Surface staining  
 
After human neutrophils isolation, cells were collected in polypropylene tube and 
washed once with PBS (EuroClone). To phenotipically characterise the expression of 
surface markers on the different PMN population, cells were incubated with a 
cocktail of antibodies diluted in PBS for 20 minutes at 4°C and then centrifuged at 
1500 RPM for 5 minutes. Pellet of human neutrophils were resuspended in PBS and 
flow cytometric analysis was performed. The antibodies described in table 5 were 
used: 
 
 
 
Antibody Clone Isotype Vendor 
Anti-CD15 HI98 Mouse IgM, k BD Bioscience 
Anti-CD66b G10F5 Mouse IgM, k BioLegend 
Anti-HLA-DR AC122 Mouse,IgG2a Miltenyi Biotec 
Anti-CD80 2D10 Mouse, IgG1,k Biolegend 
Anti-CD86 IT2.2 Mouse IgG2b, k BD Bioscience 
Anti-PD-L1 MIH Mouse, IgG1 BD Bioscience 
Anti-CD1d 51.1 Mouse, IgG2b,k BioLegend 
Anti-CXCR4 12G5 Mouse,IgG2a Miltenyi Biotec 
Anti-CD62L 145/15 Mouse, IgG1,k Miltenyi Biotec 
Anti-CD163 GHI/61 Mouse, IgG1,k BioLegend 
Anti-CD200R OX-108 Mouse, IgG1,k BioLegend 
Anti-CD54 HA58 Mouse, IgG1,k BioLegend 
Anti-CD206 DCN228 Mouse, IgG1 Miltenyi Biotec 
Anti-CD301 REA586 Recombinant Human, IgG1 Miltenyi Biotec 
 
 
         
 
 
 
To acquire and analyse cells, FACSCanto™ Cytometer (BD Bioscience) and BD 
FACSDiva™ software were used respectively. 
 
Table 5. Anti-human antibodies used for surface stainings of  human neutrophils 
cells. 
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2.3.2 Intracellular staining 
 
To analyse cytokine profiles of human neutrophils, PMN cells were collected in 15 
ml tube and washed once with PBS. After washing, cells were counted and fixed 
diluting 1 part of Fixation/ Permeabilization Concentrate with 3 parts of 
Fixation/Permeabilization Diluent (eBioscience, 100ul/ 10
6
 cells) for 20 minutes at 
room temperature (RT). In order to permeabilize cell membranes, cells were 
resuspended with Permeabilization Buffer 10X containing 0,1% saponin (BD 
Bioscience) diluted 10-fold in distilled water and centrifuged at 1500 RPM for 5 
minutes. Cells were stained with antibodies described in table 6 for 20 minutes at 
room temperature: 
 
 
Antibody Clone Isotype Vendor 
Anti- IL-10 JES3-19F1 Rat IgG2a,k BD Bioscience 
Anti- IFN-y 48B3 Mouse IgG1,k eBioscience 
 
 
        
 
 
 
After washing in permeabilization buffer, cells where resuspended in PBS and 
subsequently acquired on a BD FACSCanto™ ( BD Bioscience) cytofluorimeter. 
Analysis was performed by using BD FACSDiva™ software. 
 
 
 
 
 
 
 
 
Table 6: Anti-human antibodies used for intracellular stainings of  human 
neutrophils cells 
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2.4 HUMAN NEUTROPHILS STIMULATION 
 
2.4.1 Luminal and mucusa-associated bacteria extraction 
 
Human feces and mucus from gut of healthy controls and IBD and CRC patients 
were diluted with TES buffer containing 1M Tris-HCl, 5M NaCl and 0,5M EDTA 
and then centrifuged at 1200 RPM for 7 minutes. Samples were frozen at -80°C. In 
order to thaw cells, cryovials were incubated at 37 °C until they where thawed.   
 
2.4.2 Bacterial infection and human PMN stimulation  
 
Human PMN  cells (300.000 cells/well) isolated from blood of CTR or IBD/CRC 
patients were incubated with luminal and mucus-associated-bacteria of gut into 96-
well plates at 37 °C for 30 minutes. After this period, RPMI 1640 supplemented with 
1% Penicillin/Streptomycin (Lonza) was added with final volume of 200 ul/well. In 
addition, the same number of cells were incubated with the respective TLR ligands in 
the same final volume. The final concentration of TLR ligands in the colture were: 
0,2 ug/ml of LPS, 0,2 ug/ml Pam3 and 100 ug/ml of Poly(I:C). After incubation at 
37°C, 5% CO2, supernatants were collected for ELISA. 
 
 
2.4.3 Cytokine determination by Enzyme Immunosorbent 
Assay (ELISA) 
 
Released cytokines from human PMN assays, were measured by ELISA. ELISA 
plates (Maxisorp, Nunc) were coated with the capture antibodies over night (ON) at 4 
°C, dissolved in PBS at a concentration from 1-10 ug/ml. The incubation of the 
coating antibody was done using 50 ul of antibody solution per well. After coating, 
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the ELISA plates were washed once with washing buffer containing PBS and 0,05% 
Tween 20 (Fluka) and wells were blocked with 100 ul of blocking buffer containing 
PBS, 0,05% Tween 20 and 1% bovine serum albumin (BSA, Sigma-Aldrich) for at 
least 1 hr with 50 ul of the sample or the standard recombinant cytokine. Then plates 
were whashed three times with washing buffer and incubated for at least 1hr with 50 
ul of the detection antibody, diluted in blocking buffer at 1-5 ug/ml. After incubation 
plates were washed again three times and incubated with 60 ul of Streptavidin-HRP 
conjugate, Zymed) diluted in blocking buffer 1:4000. After 1 hr of incubation, plates 
were washed three times with washing buffer and incubated with 50 ul of the liquid 
substrate (3,3′,5,5′-Tetramethylbenzidine, TMB, ThermoFisher Scientific). The 
substrate incubation was done for 2 minutes and then stopped by addition of HCl . 
The adsorption was read at 450 nm, with ELISA reader (Plate Reader, Das). The 
samples were expressed as duplicates or triplicates, and the concentration of 
cytokines was calculated with a standard curve made by serial dilutions of the 
appropriate recombinant cytokine (Pharmigen). 
 
 
The antibodies used for ELISA were described in table 7: 
 
 
Antibody Clone Isotype Vendor 
Anti- IFN-Y Purified,MD-1 
Biotinylated 4S.B3 
Mouse, IgG1,k 
Mouse IgG1,k 
Biolegend 
Anti-IL-10 Purified JES3-19F1 
Biotinylated JES3-12G8 
Rat IgG2a 
Rat IgG2a,k 
Pharmigen 
Biolegend 
Anti-IL-23 Purified MT86/221 
Biotinylated MT155 
 MABTECH 
Anti IL-12 
(P70) 
Purified 7B12 
Biotinylated MT155 
Rat IgG1 
 
Biolegend 
 
 
 
 
 
 
Table 7: Anti-human antibodies used for cytokines quantification   
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CHAPTER 3 
 
AIMs OF THE PROJECT 
 
As known, intestinal tissue of patients with active inflammatory bowel 
disease and colorectal cancer is heavily infiltrated by innate and adaptive 
immune cells, including granulocytes, macrophages and T and B 
lymphocytes. At present, the functional role of tissutal neutrophils in the 
modulation of mucosal immune responses in IBD and CRC is still largely 
unknown. Similarly, whether mucosal neutrophils play different roles in 
these two clinical conditions is still debated.  In murine models of intestinal 
inflammation and cancer, a change in neutrophil phenotype and its possible   
functional consequence has already been described. However, there are 
limited data about the phenotype and function of neutrophil subsets in 
humans. In particular, the role of Tumor-associated neutrophils (TANs) in 
tumor development and promotion is beginning to be investigated in 
murine models, but it remains largely unexplored in humans. 
 
On this basis, we focused our attention to circulating and tissutal human 
neutrophils isolated from patients with IBD, CRC patients and controls. 
Furthermore, we aimed to investigate the role of intestinal microbiota in the 
modulation of neutrophil functions. 
 
 
The aims of this project are therefore to: 
 
 Phenotipically characterize different human neutrophil subpopulations in 
IBD and CRC patients as compared with healthy individuals. 
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 Functional characterize PMN subpopulations in IBD and CRC, as 
evaluated by cytokine and ROS production  
 
 To assess the response of IBD and CRC neutrophils to luminal and 
mucosa-associated bacterial stimulation. 
 
 Determine whether a correlation exist between relative percentage of 
circulating and tissue-associated neutrophil subsets and therapy in IBD and 
CRC patients.  
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CHAPTER 4 
 
RESULTS 
 
Neutrophils play a critical role in tumor biology (Mantovani et al., 2011 and Piccard 
et al., 2012) and during intestinal chronic inflammation (Fournier et al., 2012), with 
different and often opposing functions. To explain these observations, it has been 
postulated the existence of distinct circulating and tissue-associated neutrophils 
subpopulations (Kolaczkowska E. et al., 2013).  
 
4.1 Two subsets of neutrophils are identified in peripheral 
blood and intestinal tissue  
 
Circulating human neutrophils are characterized in cancer patients by the expression 
of the molecules CD15
 
and by the upregulation of the molecule CD66b (Ilie M. et al., 
 2012). We used this marker combination to identify circulating neutrophils not only 
in intestinal cancer patients but also in IBD patients and in healthy individuals.  
Moreover, we asked whether these markers might be useful to identify tissue-
associated neutrophils in the lamina propria of IBD patients, of CRC patients and of 
healthy individuals (Fig.12).  
 
By cytofluorimetric analysis we evaluated the frequency of CD15
+
CD66b
+
 
neutrophils in blood and lamina propria (Fig.12). 
 
We observed the existence of two distinct subsets of neutrophils on the basis of the 
expression levels of CD15 and CD66b both in blood (Fig. 12A) and in the intestinal 
tissue (Fig. 12C). The first subset was characterised by an increased expression of 
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CD66b. We will refer to this subset as CD15
+
CD66b
high
 throughout the thesis. The 
second subset was characterised by a lower expression of CD66b and we will refer to 
this subset as CD15
int
CD66b
int 
(Fig.12A,C).  
 
The relative frequency of these two subpopulations in blood and in the lamina propria 
was clearly different (Fig.12B,D), with an enrichment of the CD15
+
CD66b
high
 in the 
gut tissue as compared to blood, where it was more abundant the  CD15
int
CD66b
int
 
population, especially in IBD and CRC patients (Fig. 12C). 
 
 
 
 
 
 
 
 
 
Fig 12. Human PMN subsets are identified on the basis of CD15 and CD66b expression. 
Representative dot plots of human PMN isolated from blood (A) and gut tissue (C), and 
identified by the expression of CD15 and CD66b. (B) Data represent means ±SD of healthy 
(n=6), IBD (n=23) and CRC (n=10) patients in blood, and (D) healthy (n=10), IBD (n=19) 
and CRC (n=8) patients in gut tissue. ****p<0.0001, **p<0.01 and  *p<0.05, Student's t-test. 
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4.2 Phenotypic characterization of CD15
+
/CD66b
high
 and 
CD15
int
/CD66b
int
 subpopulations by surface markers. 
 
To further characterize the two neutrophil subsets identified in blood and intestinal 
tissue of patients and healthy individuals, we analysed a panel of surface molecules, 
known to be modulated according to the specific tissue distribution and effector 
functions (Z. G. Fridlender et al., 2009).  
 
4.2.1 Expression of antigen presenting molecules: HLA-DR 
and CD1d 
 
In addition to the phagocytic functions of neutrophils, PMN can also present antigens 
to CD4
+
T cells (Radsak et al, 2000) and to non-conventional T cells (De Santo 2010). 
For these reasons, we evaluated the expression of surface molecules linked to T cell 
activation, such as HLA-DR (Fig. 13) and CD1d (Fig.14) that present antigens to 
CD4
+
T cells and iNKT cells, respectively. 
 
Interestingly, we observed an opposite trend between circulating and tissue-
infiltrating neutrophil subsets expressing HLA-DR molecules. HLA-DR
+
 neutrophils 
in blood were almost exclusively CD15
int
CD66b
int
, while in the lamina propria of 
healthy individuals and inside CRC tumours the vast majority of HLA-DR
+
 
neutrophils belonged to the CD15
+
CD66b
high
 subpopulation. A notable exception was 
observed in IBD patients, where HLA-DR+ cells neutrophils were, similarly to those 
circulating, mostly falling into the CD15
int
CD66b
int
 subset.  
 
We observed that the overall HLA-DR expression is higher in the gut as compared to 
the blood (Fig. 13C,D). Moreover, the expression levels of HLA-DR did not differ 
between the two subsets.  To note, in the mucosa of IBD patients, HLA-DR 
expression levels on the CD15
int
CD66b
int
 population was twice as high than that of 
CD15
+
CD66b
high
 neutrophil subset (Fig. 13C, D).  
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Similarly to what observed for HLA-DR, CD1d expression varied between 
circulating and tissue-associated neutrophils (Fig.14A, B). As for HLA-DR, CD1d
+
 
neutrophils in blood were almost exclusively CD15
int
CD66b
int
, while in the lamina 
propria of IBD and CRC patients the majority of CD1d
+
 neutrophils were 
CD15
+
CD66b
high
; notably, in the lamina propria of healthy individuals no difference 
was observed between the two subsets of neutrophils concerning relative CD1d 
frequency (Fig. 14B).  
Fig. 13. HLA-DR is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of HLA-DR
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of HLA-DR (referred as Mean Fluorescence 
Intensity, MFI) on CD15
+
CD66b
high
 (C) and CD15
int
CD66b
int
 (D) neutrophils isolated from blood 
and gut tissue of IBD  and CRC patients and healthy controls. Data represented as mean ±SD of 
healthy (n=8), IBD (n=16) and CRC (n=8) patients in blood, and healthy (n=6), IBD (n=3) and 
CRC (n=5) patients in gut tissue. **p<0.01 and *p<0.05, Student's t-test. 
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As for HLA-DR, the two subsets did not show major differences in the expression 
levels of CD1d (Fig.14C,D). CD1d levels were generally higher in healthy 
individuals than in IBD-derived neutrophils. Conversely, inside the tumors both 
subsets expressed higher levels of CD1d, with the CD15
+
CD66b
high
 subset expressing 
the highest levels (Fig. 14C,D). 
 
 
 
 
 
 
 
                
 
 
 
 
 
 
Fig.14. CD1d is differentially expressed on circulating and tissue-resident neutrophil 
subsets.  Frequency of CD1d
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of CD1d (referred as Mean Fluorescence 
Intensity, MFI) on CD15
+
CD66b
high
 (C) and CD15
int
CD66b
int
 (D) neutrophils isolated from blood 
and gut tissue of IBD  and CRC patients and healthy controls. CD1d.  Data represented as mean 
±SD of healthy (n=3), IBD (n=7) and CRC (n=5) patients in blood, and healthy (n=4), IBD (n=7) 
and CRC (n=5) patients in gut tissue. *p<0.05, Student's t-test.  
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4.2.2 Expression of co-stimulatory and inhibitory molecules: 
CD86 and PD-L1 
 
Co-stimulatory and inhibitory molecules expression is associated with specific 
functional behaviours inside tissues (Gregory D. et al, 2013).  
 
Thus, we investigated the expression patterns of the co-stimulatory molecule CD86 
and the inhibitory molecule PD-L1 (also known as B7-H1) by the two subsets of 
human neutrophils, in blood and in intestinal tissue.  
 
In line with the frequency of cells expressing antigen-presenting molecules in the 
different compartments, also CD86 was expressed by the vast majority of circulating 
CD15
int
CD66b
int
 neutrophils subpopulation (Fig.15A), while in the tissue it was 
mostly expressed by the CD15
int
CD66b
int
 one (Fig. 15B). 
 
The expression levels of CD86 did not differ substantially between the two subsets 
(Fig.15C), although the circulating CD15
+
CD66b
high
 subpopulation expressed this co-
stimulatory molecule at higher levels as compared to the gut (Fig.15D). 
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Fig. 15. CD86 is differentially expressed on circulating and tissue-resident neutrophil subsets . 
Frequency of CD86
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and CRC patients and 
healthy controls. Expression levels of CD86 (referred as Mean Fluorescence Intensity, MFI) on 
CD15
+
CD66b
high
 (C) and CD15
int
CD66b
int
 (D) neutrophils isolated from blood and gut tissue of IBD  
and CRC patients and healthy controls. Data represented as mean ± SD of healthy (n=3), IBD (n=8) 
and CRC (n=6) patients in blood, and healthy (n=4), IBD (n=4) and CRC (n=3) patients in gut tissue. 
*p<0.05, Student's t-test. 
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PD-L1 was expressed almost exclusively by CD15
int
CD66b
int
 circulating neutrophils 
isolated from healthy individuals and from IBD patients, while surprisingly by very 
few of those isolated from CRC patients (Fig. 16A).  
 
In the gut, the differences between the two subpopulations were almost absent in 
terms of frequency. Interestingly, PD-L1 was expressed by a higher fraction of 
neutrophils isolated from healthy individuals as compared to IBD or to CRC patients 
(Fig.16B). 
 
The general expression levels of PD-L1 were higher in the CD15
+
CD66b
high
 subset as 
compared to the intermediate, but we did not observe striking differences between 
groups of patients and healthy individuals (Fig.16C,D). 
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Fig. 16. PD-L1 is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of PD-L1
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of PD-L1 on CD15
+
CD66b
high
 (C) and 
CD15
int
CD66b
int
 (D) neutrophils isolated from blood and gut tissue of IBD and CRC patients 
and healthy controls. Data represented as mean± SD of healthy (n=4), IBD (n=8) and CRC 
(n=4) patients in blood, and healthy (n=6), IBD (n=4) and CRC (n=4) patients in gut tissue.  
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4.2.3 Expression of molecules involved in neutrophil 
trafficking: CXCR4, CD54 and CD62L 
 
 
Neutrophil recruitment to the site of injury is an essential first step of an anti-bacterial 
response, but it is also essential for tumor infiltration (Kolaczkowska E. at al, 2013).  
Thus, we evaluated the possibility that the two neutrophils subsets isolated from IBD 
and/or CRC patients might manifest modifications in the expression pattern of 
molecules involved in trafficking.   
 
We selected CXCR4, which is expressed upon inflammatory stimuli (Christoffersson 
et al., 2012) and is overexpressed in human cancers (Uhlen,& Rhim, 2010), CD54  
(also known as ICAM-1) which is important for neutrophil transmigration through 
the endothelial monolayer, and CD62L also known as L-selectin, that facilitates 
infiltration of neutrophils into the site of inflammation.  
 
As expected for a homing molecule, CXCR4 was expressed at higher levels in the 
tissues as compared to the blood (Fig.17A,B) but we did not observed a different 
expression between the two subpopulations. 
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CD54 was expressed by circulating neutrophils isolated from IBD and CRC patients, 
but it was mostly absent on the surface of neutrophils isolated from healthy 
individuals (both circulating and in the gut) and no differences were observed among 
the two sub-populations. Conversely, CD54 was expressed in the gut almost 
exclusively by CD15
+
CD66b
high
 cells (Fig. 18B). The expression levels of CD54 were 
Fig. 17. CXCR4 is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of CXCR4
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of CXCR4 on CD15
+
CD66b
high
 (C) and 
CD15
int
CD66b
int
 (D) neutrophils isolated from blood and gut tissue of IBD and CRC patients 
and healthy controls. Data represented as mean ± SD of healthy (n=3), IBD (n=11) and CRC 
(n=5) patients in blood, and healthy (n=3), IBD (n=3) and CRC (n=4) patients in gut tissue. 
***p<0.001, **p<0.01 and *p<0.05, Student's t-test. 
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higher in IBD and CRC patients as compared to healthy individuals, with no 
significant differences between the two subpopulations (Fig. 18C,D). 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig. 18. CD54 is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of CD54
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  
and CRC patients and healthy controls. Expression levels of CD54 on CD15
+
CD66b
high
 
(C) and CD15
int
CD66b
int
 (D) neutrophils isolated from blood and gut tissue of IBD and 
CRC patients and healthy controls. Data represent means ± SD of healthy (n=3), IBD 
(n=7) and CRC (n=3) patients in blood, and healthy (n=4), IBD (n=9) and CRC (n=2) 
patients in gut tissue.  
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Finally, CD62L was expressed exclusively by circulating CD15
int
CD66b
int
 
neutrophils of IBD and CRC patients, but it was expressed only on a small fraction of 
neutrophils of healthy individuals. In the gut, as it was observed for other surface 
molecules, CD15
+
CD66b
high 
cells from IBD and CRC patients were the cells mostly 
expressing CD62L (Fig. 19A,B).  
 
Interestingly, expression levels of CD62L were variable on the surface of neutrophils, 
although CD15
int
CD66b
int 
cells isolated from the lamina propria expressed higher 
levels of CD62L than their circulating counterpart.  
 
Moreover, CD15
+
CD66b
high
 cells isolated from healthy individuals and CRC patients 
seemed to express higher levels of CD62L as compared to those isolated IBD 
patients.  
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Fig.19. CD62L is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of CD62L
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of CD62L on CD15
+
CD66b
high
 (C) and 
CD15
int
CD66b
int
 (D) neutrophils isolated from blood and gut tissue of IBD and CRC patients 
and healthy controls. Data represented as mean± SD of healthy (n=2), IBD (n=5) and CRC 
(n=2) patients in blood, and healthy. (n=2), IBD (n=2) and CRC (n=2) patients in gut tissue. 
***p<0.001 and *p<0.05, Student's t-test. 
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4.2.4 Clinical correlation 
 
Since we observed different frequencies of CD15
+
CD66b
high
 and CD15
int
CD66b
int 
subsets in blood and intestinal tissue of IBD and CRC patients, we asked whether 
immunomodulators could play a role in producing these alterations. Indeed, 
therapeutic regimens were highly different among patients, as shown in Tables 1,2,3 
and 4 of the material and methods section.  
 
We decided therefore to perform separate analyses on the patients based upon 
whether they were receiving or not at the time of surgical intervention. 
Immunosuppressants include thiopurines such as 6-mercaptopurine (6-MP), 
azathioprine (AZA), steroids and anti-TNF (infliximab or adalimumab). As depicted 
in Fig. 20, We observed that both  circulating PMN subsets decreased in IBD and 
CRC patients under immunosuppressive treatment. 
 
On the contrary, in the intestinal mucosa, the frequencies of the CD15
+
CD66b
high
 
population slightly increased in IBD and CRC patients under immunosuppressive 
therapy while the percentage of the CD15
int
CD66b
int
 subset strongly decreased in 
IBD and CRC patients under immunosuppressive treatment. 
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Fig.20. Immunosuppressive therapy impacts on PMN frequency in blood and gut tissue. 
Scatter dot plot represent the percentage of PMN subsets in blood and gut tissue of IBD and 
CRC patients with (in red) or without (in green) immunosuppressive therapy ongoing. 
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4.2.4.1 Antigen presenting molecules expression and clinical 
correlation  
 
Next, we correlated the expression of  antigen presenting molecules on the surface of 
the two PMN subsets in blood and intestinal tissue of IBD and CRC patients with or 
without immunosuppressive treatment (Fig.21).  
 
HLA-DR expression on the CD15
+
CD66b
high
 subset did not correlate with ongoing 
therapy. On the contrary, it did correlate in IBD patients, demonstrating a strong 
increase of HLA-DR
+
 cells among CD15
int
CD66b
int
 subsets in patients under 
immunosuppressive therapy (Fig 21A). 
 
CD1d expression on both subsets and similarly in IBD and CRC patients was 
decreased in the intestinal tissue of patients undergoing immunosuppressive therapy 
(Fig 21B). 
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Fig.21. Immunosuppressive therapy increases HLA-DR expression on CD15
int
CD66b
int
 
neutrophils, of IBD patients. Scatter dot plot represent the percentage of PMN subsets 
expressing HLA-DR (A) and CD1d
 
(B) in blood and gut tissue of IBD and CRC patients with 
(in red) or without (in green) immunosuppressive therapy. 
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4.2.4.2 Activator and inhibitory molecules and clinical 
correlation  
 
Next, we correlated the expression of CD86 and PD-L1 on the surface of the two 
PMN subsets in blood and intestinal tissue of IBD and CRC patients with or without 
immunosuppressive treatment ongoing (Fig 22).  
 
CD86 expression on the CD15
+
CD66b
high
 subset increased in blood and in tissue of 
IBD and CRC patients undergoing immunosuppressive therapy (not in CRC patients 
gut, though) (Fig 22A). Similarly, CD86 expression on the CD15
int
CD66b
int
 subset 
strongly increased in the blood of IBD patients under therapy, but not in the gut and 
no differences were observed in CRC patients.  
 
PD-L1 expression, instead, was strongly reduced on the surface of both circulating 
and infiltrating CD15
+
CD66b
high
 neutrophils (Fig 22B) in both IBD and CRC patients 
under immunosuppressive therapy. PD-L1 expression was lower on circulating 
CD15
int
CD66b
int
 from IBD patients undergoing immunosuppressive therapy, but it 
was unchanged in the gut of both IBD and CRC patients. 
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Fig.22. Immunosuppressive therapy differently impacts on CD86 and PD-L1 expression 
of IBD and CRC PMN. Scatter dot plot represent the percentage of PMN subsets expressing 
CD86
 
(A) and PD-L1 (B) in blood and gut tissue of IBD and CRC patients with (in red) or 
without (in green) immunosuppressive therapy ongoing. 
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4.2.4.3 Expression of molecules involved in trafficking and 
clinical correlation  
 
Next, we correlated the expression of molecules involved in the migration of 
neutrophils on the surface of the two PMN subsets in blood and intestinal tissue of 
IBD and CRC patients with or without immunosuppressive treatment ongoing (Fig. 
23).  
 
CXCR4 expression on the CD15
+
CD66b
high
  subset decreased in blood and increased 
in tissue of IBD and CRC patients undergoing immunosuppressive therapy  (Fig. 
23A). On the contrary, CXCR4 expression on the CD15
int
CD66b
int
 subset was 
increased in the blood of IBD patients under therapy, but not in the gut and no 
differences were observed in CRC patients.  
 
CD54 expression, instead, was strongly reduced on the surface of both circulating 
subsets in both IBD and CRC patients under immunosuppressive therapy, and it was 
slightly increased on the surface of the CD15
int
CD66b
int
 neutrophils in the gut of IBD 
patients (Fig.23B). 
 
CD62L expression on circulating neutrophils was unaffected by immunosuppressive 
therapy, but it was decreased on the surface of gut CD15
int
CD66b
high
 neutrophils in 
both IBD and CRC patients under immunosuppressive therapy and it was slightly 
increased on the surface of the CD15
int
CD66b
int
 neutrophils in the gut of IBD patients 
(Fig.23C). 
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Fig.23. Immunosuppressive therapy modulates CXCR4, CD54 and CD62L expression on 
PNM subsets of IBD and CRC patients. Scatter dot plot represent the percentage of PMN 
subsets expressing CXCR4 (A), CD54 (B)
 
and CD62L (C) in blood and gut tissue of IBD and 
CRC patients without treatment (in red) and during immunosuppressive therapy (in green). 
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4.2.5 Expression of molecules involved in neutrophil N1/N2 
polarization 
 
 
Recent reports (Virna Cortez-Retamozo et al., 2012) demonstrated that neutrophils, 
like macrophages, may have the ability to differentiate into two distinct functional 
subsets: one more inflammatory/anti-tumorigenic (N1) and a second more anti-
inflammatory/protumorigenic (N2). 
 
To evaluate if CD15
+
CD66b
high
 and CD15
int
CD66b
int
 subsets in blood and gut tissue 
of IBD and CRC patients showed a skewed N1/N2, we phenotipically characterized 
neutrophil subsets through the expression of known N1 and N2 markers, similarly to 
those identified for M1 and M2 macrophages (Subhra KB at al., 2010). 
 
Among others, classical N1 markers are HLA-DR and CD86, that we evaluated 
separately in sections 4.2.1 (HLA-DR) and 4.2.2 (CD86).  In this section we will 
evaluate the co-expression of these N1 markers on the surface of the identified 
neutrophils subpopulations.  
Typical N2 markers instead are CD301, CD206, CD163 and CD200R (Koning N. at 
al., 2010). In this section we will evaluate these markers separately and then, as for 
N1 markers, we will evaluate their co-expression on the two subsets of neutrophils. 
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4.2.5.1 Co-Expression of molecules involved in N1 
differentiation (HLA-DR and CD86) 
 
As it was observed in Figures 13 (HLA-DR) and 15 (CD86), the expression of these 
two molecules linked to an inflammatory phenotype are associated to the 
CD15
int
CD66b
int
 population in blood and to the CD15
+
CD66b
high
 in the gut. 
 
Similarly, these N1 molecules were co-expressed by CD15
+
CD66b
high
  neutrophils in 
the gut (Fig 24). Unexpectedly, IBD patients CD15
+
CD66b
high
  neutrophils were 
“less” polarised towards an N1 phenotype as compared to CRC patients or healthy 
controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.24. Human PMN subsets expressing a N1 phenotype. Histograms showing the 
percentage of CD15
+
CD66b
high
 and CD15
int
CD66b
int
 with N1 phenotype in blood and gut tissue 
of IBD and CRC patients and controls. 
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4.2.5.2 Expression of molecules involved in N2 polarization: 
CD163, CD301, CD206 and CD200R 
 
CD163 is a member of the scavenger receptor (Onofre G., 2009). This scavenger 
receptor is selectively expressed on cells of monocytes and macrophages lineage. 
This molecule participates in adhesion to endothelial cells, in tolerance induction and 
tissues regeneration exhibiting strong anti-inflammatory properties (van Gorp H. et 
al., 2010).  
 
CD301, also known as CLEC10A, is a transmembrane glycoprotein that is expressed 
on immature myleloid dendritic cells and alternatively activated (tolerogenic) 
macrophages (Raes G. et al., 2005).  Human CD301 has an exclusive specificity for 
rare terminal GalNAc structures, which are revealed on the tumor-associated mucin 
MUC1 and CD45. This interaction inhibits effector T cell activation and induces their 
apoptosis. 
 
CD206, also known as mannose receptor (MR), is a type I membrane protein that is 
expressed on different types of cells such as macrophages and dendritic cells 
(Verreck FA. et al., 2006). This molecule recognizes a range of microbial 
carbohydrates bearing mannose, fucose, or N-acetyl glucosamine, sulfated 
carbohydrate antigens and collagens. CD206 mediates endocytosis and phagocytosis 
as well as activation of macrophages and antigen presentation. Recently, CD206 on 
lymphatic endothelial cells was found to be involved in leukocyte trafficking and a 
contributor to the metastatic behavior of cancer cells. It suggests that this molecule 
may be a potential target in controlling inflammation and cancer metastasis by 
targeting the lymphatic vasculature. 
 
CD200R, also known as OX2R, is a membrane glycoprotein expressed primarily by 
monocytes and neutrophils but also by other leukocytes including T lymphocytes and 
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mast cells (Wright GJ et al., 2003). The interaction between CD200 and CD200R 
may contribute to pathways that suppress and limit macrophage induced 
inflammatory damage in tissue.  
Analysis of CD163 revealed a more prominent expression by tissue-derived as 
compared to circulating neutrophils (Fig 25A,B), and by the CD15
+
/CD66b
high
 
subpopulation as compared to CD15
int
CD66b
int
 population, especially by neutrophils 
isolated from IBD and CRC patients (Fig.25A,B). 
To note, expression levels are higher in IBD-derived neutrophils, regardless the 
subpopulation (Fig 25C,D) 
 
 
 
 
 
 
 
 
Fig.25. CD163 is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of CD163
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of CD163 (referred as Mean Fluorescence 
Intensity, MFI) on CD15
+
CD66b
high
 (C) and CD15
int
CD66b
int
 (D) neutrophils isolated from blood 
and gut tissue of IBD  and CRC patients and healthy controls. Data represented as mean± SD of 
healthy (n=3), IBD (n=6) and CRC (n=3) patients in blood, and healthy (n=3), IBD (n=9) and 
CRC (n=2) patients in gut tissue.  
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Analysis of CD301 showed a similar pattern as for CD163. CD301 was more 
expressed by tissue-derived neutrophils (Fig.26A,B), especially by the 
CD15
+
CD66b
high
 subpopulation. Only CRC-derived CD15
int
CD66b
int
 neutrophils 
seemed to express CD301 in the gut (Fig.26A,B). 
Also expression levels reflected this trend, with tissue derived neutrophils expressing 
higher levels of CD301, but no major differences were observed among the two 
populations or among the patients type (Fig.26C,D). 
 
 
 
 
 
 
 
 
 
Fig.26. CD301 is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of CD301
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of CD301 (referred as Mean Fluorescence 
Intensity, MFI) on CD15
+
CD66b
high
 (C) and CD15
int
CD66b
int
 (D) neutrophils isolated from 
blood and gut tissue of IBD  and CRC patients and healthy controls. Data represented as mean± 
SD of healthy (n=3), IBD (n=7) and CRC (n=3) patients in blood, and healthy (n=4), IBD (n=9) 
and CRC (n=2) patients in gut tissue.  
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Analysis of CD206 was matching the results of CD163 and CD301. CD206 was more 
expressed by tissue-derived neutrophils (Fig.27A,B), especially by the 
CD15
+
CD66b
high
 subpopulation and, again, only CRC-derived CD15
int
CD66b
int 
neutrophils seemed to express CD206 in the gut (Fig.27A,B). 
Expression levels confirmed that tissue derived neutrophils expressed higher levels of 
CD206, and only IBD-derived circulating neutrophils expressed high levels of 
CD206 while no major differences were observed among the two populations or 
among the patients type in the gut (Fig.27C,D). 
 
 
 
 
 
 
 
Fig.27. CD206 is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of CD301
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of CD301 (referred as Mean Fluorescence 
Intensity, MFI) on CD15
+
CD66b
high
 (C) and CD15
int
CD66b
int
 (D) neutrophils isolated from 
blood and gut tissue of IBD  and CRC patients and healthy controls. Data represented as mean± 
SD of healthy (n=3), IBD (n=3) and CRC (n=1) patients in blood, and healthy (n=4), IBD (n=4) 
and CRC (n=2) patients in gut tissue.  
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Finally, also the analysis of CD200R perfectly paralleled that of the previous N2 
markers.  CD200R was more expressed by tissue-derived neutrophils (Fig.28A,B), 
especially by the CD15
+
CD66b
high
 subpopulation (Fig. 28A,B). 
Expression levels confirmed that tissue derived neutrophils expressed slightly higher 
levels of CD200R in the gut, with CRC-derived tissue neutrophils expressing the 
highest levels (Fig.28C,D). 
 
 
 
 
 
 
 
 
 
Fig.28. CD200R is differentially expressed on circulating and tissue-resident neutrophil 
subsets. Frequency of CD301
+
 neutrophil subsets in blood (A) and gut tissue (B) of IBD  and 
CRC patients and healthy controls. Expression levels of CD301 (referred as Mean Fluorescence 
Intensity, MFI) on CD15
+
CD66b
high
 (C) and CD15
int
CD66b
int
 (D) neutrophils isolated from 
blood and gut tissue of IBD  and CRC patients and healthy controls. Data represented as mean± 
SD of healthy (n=3), IBD (n=7) and CRC (n=3) patients in blood, and healthy (n=4), IBD (n=9) 
and CRC (n=2) patients in gut tissue.  
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Finally, as we did for N1-associated markers co-expression, we evaluated the co-
expression of N2-associated molecules. We found that the CD15
+
/CD66b
high
 
population was mostly associated with an N2 phenotype in the gut (Fig.29), both 
when we compared the co-expression of CD206 and CD301 (Fig.29A,B) and of 
CD163 and CD200R
 
(Fig.29C,D). Co-expression of CD163 and CD200R was the 
only combination of N2 markers that distinguished CD15
+/
CD66b
high
 isolated from 
healthy individuals from those isolated from IBD or CRC patients (Fig 29D). 
 
 
 
 
 
 
 
Fig.29. Human PMN subsets expressing a N2 phenotype. Histograms showing the percentage 
of CD15
+
CD66b
high
 and CD15
int
CD66b
int
 neutrophils with N2 phenotype in blood and gut tissue 
of patients and controls. 
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Table 8 summarizes some of the differences concerning the expression of surface 
markers on CD15
+
CD66b
high
 and CD15
int
CD66b
int
 PMN subsets in blood and gut 
tissue of patients and healthy individuals. 
 
 CD15
+
CD66b
high
 CD15
+
CD66b
high
 CD15
int
CD66b
int
 CD15
int
CD66b
int
 
 Blood Gut Tissue Blood Gut tissue 
 Healthy IBD CRC Healthy IBD CRC Healthy IBD CRC Healthy IBD CRC 
HLA-
DR 
+ + + ++ + ++ + + + ++ ++ ++ 
CD1d +++ +++ ++ +++ ++ ++++ +++ ++ ++ +++ ++ +++ 
CD86 +++ +++ +++ ++ ++ ++ ++ ++ ++ ++ ++ + 
PD-L1 ++ ++ ++ +++ + ++ + + ++ ++ + + 
CD54 ++ ++ ++ + ++ ++ + ++ + + ++ ++ 
CXCR4 ++ ++ ++ +++ ++ ++ ++ + + +++ ++ ++ 
CD62L + + + + + + + + + + + + 
CD163 ++ +++ ++ + +++ + + +++ + + ++ + 
CD301 + + ++ ++ ++ ++ + + + ++ + ++ 
CD206 + ++ ++ ++ ++ ++ + ++ + ++ ++ ++ 
CD200R + + + + + + + + + + + ++ 
+=MFI,<3000; ++=MFI,>3001-10000; +++=MFI,>10001-40000; ++++=MFI,>40001  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Expression levels (calculated as MFI) of surface markers on human neutrophil subsets 
isolated from blood and gut tissue of IBD and CRC patients, and healthy controls.  
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4.2.5.3 N1 and N2 phenotype and clinical correlation  
 
Since we did not observe major differences concerning N1/N2 polarization in the 
patients analysed, we asked whether different treatments might influence the 
phenotypical polarization of neutrophils. 
 
4.2.5.4 Correlation between N1 phenotype and therapies 
 
To evaluate if the use of specific immunosuppressive drugs had an impact on 
polarization towards the N1 phenotype of circulating and tissue-derived neutrophils, 
we compared the frequency of CD15
+
CD66b
high
 and CD15
int
CD66b
int
 subsets in 
blood and tissue of IBD and CRC patients undergoing or not immunosuppressive 
therapy (Fig.30). Although we had the possibility to perform this correlation on a 
limited number of patients, we observed a decrease of CD15
+
CD66b
high
 cells with N1 
phenotype in both IBD and CRC patients under immunosuppressive therapy. 
 
 
 
 
 
Fig.30. Immunosuppressive therapy decreases the frequency of tissue resident N1 
CD15
+
CD66b
high
. Scatter dot plots showed frequencies of  PMN subsets with N1 phenotype in 
blood and gut tissue of IBD and CRC patients with (green) or without (red) immunosuppressive 
therapy. 
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Similarly to evaluate if the use of specific immunosuppressive drugs had an impact 
on polarization towards the N2 phenotype of circulating and tissue-derived 
neutrophils, we compared the frequency of CD15
+
CD66b
high
 and CD15
int
CD66b
int
 
subsets in blood and tissue of IBD and CRC patients undergoing or not 
immunosuppressive therapy, as reported before in Fig 30. As showed in Figure 31, 
the frequency of both circulating and infiltrating neutrophil subsets with N2 
phenotype decreased upon immunosuppressive treatment, especially in IBD patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.31. Immunosuppressive therapy decreases the frequency of N2 neutrophil subsets. 
Scatter dot plots showed frequencies of PMN subsets with N2 phenotype in blood and gut tissue 
of IBD and CRC patients with (green) or without (red) immunosuppressive therapy. 
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4.2.5.5 Correlation between  N1/N2 polarisation in UC and CD 
patients and therapies 
 
Firstly we analysed the frequency of polarised N1/N2 subsets among 
CD15
+
CD66b
high
 and CD15
int
CD66b
int
 neutrophils in blood and intestinal tissues of 
CD and UC patients (Fig.32).  
 
As shown in Figure 32, both CD15
+
/CD66b
high
 neutrophils increased in the gut of CD  
patients showing a stronger skew towards a N2 phenotype (70% N2 vs 20% N1). In 
UC patients, even CD15
+
CD66b
high
 with N2 phenotype were strongly accumulating 
in the intestinal mucosa of the patients rather than in blood.  The frequency of 
circulating and tissue CD15
int
CD66b
int
 cells was generally very low in both UC and 
CD patients (Fig 32B,C). 
 
 
 
 
 
Fig.32. Circulating and tissue-derived  CD15
+
CD66b
high
  neutrophils expressing N2 
phenotype are increased in both UC and CD patients. Scatter dot plot showed the percentage 
of CD15
+
CD66b
high
 (A-C) and CD15
int
CD66b
int
 (B-D) cells with N1 (A-B) and N2 (C-D) 
phenotype in blood and gut tissue of CD and UC patients. 
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To evaluate if immunosuppressive therapy had an impact on the polarization of 
neutrophils subsets of CD and UC patients, we compared the frequency of 
CD15
+
CD66b
high
 and CD15
int
CD66b
int
 subsets in blood and tissue of these patients 
with or without immunosuppressive therapy ongoing. As reported in Fig.33, the 
frequency of both circulating and tissue derived N2-skewed CD15
+
CD66b
high 
neutrophils isolated from CD and UC patients under immunosuppressive therapy was 
strongly decreased.  
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Fig.33. Immunosuppressive therapy decreases the frequency of N2 polarized neutrophils. 
Scatter dot plots showed frequencies of CD15
+
CD66b
high
 with N1 (A) and N2 (B) phenotype in 
blood and gut tissue of CD and UC patients with (green) or without (red) immunosuppressive 
therapy. 
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4.3 Functional characterization of CD15
+
/CD66b
high
 and 
CD15
int
/CD66b
int
 neutrophil subpopulations  
 
Immunomodulatory function of neutrophil cells is strongly associated to the secretion 
of a different array of cytokines, that, similarly to human macrophages, are capable to 
suppress or enhance immune responses (A. Mantovani et al., 2002; S. Gordon et al., 
2005; A. Mantovani et al., 2012).  
 
In order to functionally characterise the human neutrophils subsets isolated from 
healthy individuals and IBD and CRC patients in blood and in the gut, we decided to 
perform different types of analyses. Firstly, we evaluated the cytokine profile of 
neutrophils (Fig.34,35) and then we evaluated their functional response upon 
bacterial stimulation (Fig.36). 
 
4.3.1 Ex vivo cytokine secretion by neutrophil subsets  
 
Freshly isolated human neutrophils were evaluated for their ability to secrete IFN-γ, a 
N1- derived pro-inflammatory cytokine, and IL-10, the prototypic N2 anti-
inflammatory cytokine (Saraiva et al., 2010) which is implicated, among other 
functions, in the maintenance of gut homeostasis (Balk SP et al.,1994). 
Figure 34A showed representative dot plots of IL-10 and IFN- γ released by human 
PMN subsets in blood and intestinal tissue of healthy individuals, IBD patients and 
CRC patients. 
Surprisingly, the analyses did not show a clear skewed production of cytokines by the 
two populations of neutrophils, neither concerning the type of patients (CRC/IBD vs 
healthy) nor regarding the tissue localization (blood vs gut) (Fig. 34, 35). 
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Both CD15
+
/CD66b
high
 and CD15
int
/CD66b
int
 human neutrophil subsets were able to 
secrete higher levels of IL-10 in the gut as compared to blood. Although not 
significant, there was a tendency in CRC patients to secrete more IL-10 as compared 
to IBD patients and controls (Fig. 35A,B).  
 
On the contrary, CD15
+
/CD66b
high
 neutrophils secreted lower levels of IFN-γ in the 
gut of IBD patients and healthy controls as compared with blood (Fig. 35C,D).  
 
Interestingly, neutrophils isolated from CRC patients were able to secrete IFN-γ, 
suggesting a potential contribution to anti-tumor immune functions in the gut. 
 
 
 
 
Fig.34. IL-10 and IFN-Y production by human PMN subsets in blood and gut tissue of 
patients and controls. Representative dot plots showing IFN-γ and IL-10 production by 
CD15
+
CD66b
high
 and CD15
int
CD66b
high
 in blood and gut tissue of patients and healthy 
individuals. 
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Fig.35. IL-10 and IFN-Y production by human PMN subsets in blood and gut tissue of 
patients and controls. Histograms showing IL-10 (A-B) and IFN- γ (C-D) secretion by PMN 
subsets in blood and gut tissue of patients and healthy individuals. 
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4.3.2 Cytokine secretion upon TLR in vitro stimulation  
 
To investigate which were the stimuli driving the observed cytokine production by 
neutrophils in vivo, we stimulated freshly isolated human PMN with different 
bacterial stimuli. To note, we encountered several methodological difficulties to 
perform in vitro experiments with ex-vivo isolated human neutrophils, mainly due to 
their low vitality, additionally compromised after the long protocol of lamina propria 
cell isolation from intestinal tissues. Moreover, cytofluorimetric separation of 
neutrophils was further reducing their functional capabilities (data not shown). 
 
We stimulated in vitro neutrophils with different TLR ligands, for 24h. Since 
neutrophils express TLR4, TLR3 and TLR2 (Underhill DM. et al., 2002), we 
stimulate them with LPS (TLR4L), Poly I:C (TLR3L) and Pam3Cys (TLR2L) (Fig. 
36A) . As a read out, we analyzed a panel of pro- and anti-inflammatory cytokines 
such as IFN-γ, IL12p70, IL23 and IL-10.After in vitro stimulation, only blood-
derived human PMN were able to secrete cytokines, while tissue- derived neutrophils 
were completely unable to do so. In addition, the only cytokine that we were able to 
detect in the culture supernatants was IL-10 after LPS -driven TLR4 triggering (Fig. 
36B).  
 
 
 
 
 
 
 
Fig. 36. TLR4 stimulation induces IL-10 production by circulating PMN.  Human neutrophils 
were stimulated  with different TLR ligands and supernatants were tested by ELISA (A). 
Histograms represent IL-10 released by human neutrophils after bacteria stimuli (B). 
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4.3.3 Cytokine secretion upon total luminal/mucosal bacteria 
in vitro stimulation  
 
IBD and CRC patients are characterized by gut bacterial dysbiosis (Iradj Sobhani et 
al., 2011; C P Tamboli et al., 2004). To evaluate if a dysbiotic microbiota could 
influence the observed cytokine production by PMNs, we analyzed cytokines 
producted by neutrophils after exposure to autologous luminal and mucus-associated 
bacteria (Fig.37).  
 
When circulating human PMN isolated from patients and healthy individuals were 
stimulated with bacteria, we observed that neutrophils from CRC patients secreted 
significant amount of IL-10 but almost no IL12p70 (Fig.37A,B). Conversely, 
neutrophils isolated from healthy individuals and from IBD patients secreted mostly 
IL12p70 and almost no IL-10 (Fig.37A,B). 
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Fig. 37. Bacterial stimulation induced  IL-10 and IL-12 production by human PMN of 
IBD, CRC and healthy individuals. Histograms represent IL-10 (upper panel) and IL-12 
(lower panel) cytokine production by neutrophils stimulated with luminal (brown bar) or 
mucosal (red bars) bacteria, for 24 hours. Supernatant were tested by ELISA. 
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4.3.4 ROS production upon total luminal/mucosal bacteria in 
vitro stimulation  
 
Although we observed cytokine production by neutrophils, it is well known that one 
of the primary functional outcomes of neutrophils activation upon bacterial 
stimulation  is the production of  Reactive Oxygen Species (ROS). To better  
understand the effects of intestinal bacteria on neutrophils ROS production, we 
stimulated in vitro  blood-derived neutrophils with luminal and mucus-associated 
bacteria from IBD, CRC and healthy individuals. ROS production was measured by 
flow cytometry using an oxidant-sensitive probe DHR123 (DHR) that upon 
interaction with free radicals, is oxidized, resulting in the liberation of rhodamine123, 
a highly fluorescent molecule. 
 
As it is shown in Figure 38, luminal and mucosa-associated bacterial stimulation 
induces ROS production by neutrophils isolated from healthy individuals and from 
IBD and CRC patients. Interestingly, neutrophils isolated from peripheral blood of  
IBD patients (Fig. 38B,C) seemed to react more intensely to bacterial stimulation 
than neutrophils isolated from CRC patients and from healthy individuals (Fig. 
38B,C). 
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Fig. 38. Neutrophils produce ROS following bacterial stimulation. Neutrophils were 
stimulated with luminal and mucosal bacteria of CRC patients, IBD patients  and healthy 
individuals. Cells were stained with DHE and ROS production was analyzed by FACS. 
Histograms represent ROS production (A), analysis of MFI (B) and frequency of PMN cells 
(C) that release ROS after luminal (orange bars) and mucosal bacteria stimuli (brown bars). 
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DISCUSSION 
Intestinal tissue of patients with active inflammatory bowel disease and colorectal 
cancer is heavily infiltrated by innate and adaptive immune cells, including 
granulocytes, macrophages and T and B lymphocytes. At present, the functional role 
of tissutal neutrophils in the modulation of mucosal immune responses in IBD and 
CRC is still largely unknown. Similarly, whether mucosal neutrophils play different 
roles in these two clinical conditions is still debated.  In murine models of intestinal 
inflammation and cancer, a change in neutrophil phenotype and its possible   
functional consequence has already been described. However, there are limited data 
about the phenotype and function of neutrophil subsets in humans. In particular, the 
role of Tumor-associated neutrophils (TANs) in tumor development and promotion is 
beginning to be investigated in murine models, but it remains largely unexplored in 
humans. 
In this thesis, we focused our attention to circulating and tissutal human neutrophils 
isolated from patients with IBD, CRC patients and controls. We extensively 
characterized them phenotipically and we evaluated if the differences observed 
among groups of patients might correlate with specific therapies.  
Firstly, we isolated neutrophils from blood and intestinal tissue of IBD and CRC 
patients and from healthy individuals. While isolation of neutrophils from blood takes 
advantage from a well known and standardized protocol, i.e. the Dextran 
sedimentation followed by Ficoll-Paque density gradients, to isolate PMN from 
lamina propria we were forced to adapt a protocol previously described by 
Monteleone (Monteleone G et al., 1997). Indeed, currently few methodologies to 
isolate neutrophils from intestinal surgical specimens are described. The major 
implementation to the Monteleone protocol that we introduced was to shorten the 
protocol since we realized that our greatest limitation to perform subsequent analyses 
with freshly isolated intestinal neutrophils was their short life span and their high 
susceptibility to toxic agents. Neutrophils have long been considered to be a 
relatively homogeneous cell population. Emerging data have now confirmed that, 
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rather than being an end-stage uniform cell population, neutrophils can show a great 
level of plasticity and display distinct phenotypes and/or subsets in response to a wide 
range of physiological and pathological (e.g. inflammation and infection) conditions 
similarly to lymphocytes (Miller JFAP. 2002; Bluestone JA et al., 2009; Matthias P et 
al.,2005; Hirahara K et al., 2011) and monocytes (Auffray C et al., 2009). 
Measurement of surface receptor expression on neutrophils is often used for the 
evaluation of systemic inflammation in peripheral blood (Fortunati E et al., 2009). 
Changes in the surface expression levels of specific molecules on leucocytes is often 
associated with an activated phenotype and correlates with an augmented chemotaxis 
and transendothelial migration in vitro (Warringa RA et al., 1993; Schymeinsky J et 
al., 2007). Similarly, under certain pathological conditions, neutrophils are able to 
differentiate into different subsets, each one characterized by unique phenotype and 
functional proﬁle (Scapini P et al., 2014; Sagiv JY et al.,2015).  
Upon cytofluorimetric analyses of circulating and tissue-derived neutrophils, we were 
capable to identify two distinct subsets of human PMN differentially expressed in 
blood and intestinal tissue of patients with IBD, colorectal cancer and healthy 
individuals.  
These two subsets were characterized by different expression levels of the surface 
molecules CD15 and CD66b. CD15 is a molecule associated to human neutrophils, 
and it is highly expressed on tumor-associated neutrophils (Eruslanov EB et al., 
2014).CD66b, instead, was shown to be up-regulated on intratumoral neutrophils in 
patients with resectable non small cell lung cancer (Ilie M. et al.,  2012).  
Recent studies though, showed that CD15 was expressed also in granulocytic human 
myeloid-derived suppressor cells (G-MDSC) that are present in low numbers in the 
blood of healthy donors (Paul R et al., 2016) but are abundantly increased in the 
blood of patients with specific tumor types (Paul R et al., 2016). In mice, these cells 
are defined by expression of CD11b
+
Gr-1
high
Ly-6G
+
Ly-6C
low
 cells (Youn JI et al., 
2008). In humans, neutrophils lack a marker similar to Ly6G and various studies have 
used different criteria for recognizing different phenotypes of MDSCs (Solito S. et 
82 
 
al., 2014). MDSC are morphologically and phenotipically similar to neutrophils, 
which raises the possibility that neutrophils in an activated state are in fact G-MDSC.  
Throughout the thesis work we were perfectly aware that cells with a similar 
phenotype (and possibly similar in vivo function) to that we described for our 
neutrophils were either called “MDSC” or “neutrophils” by different investigators 
both in cancer patients and in tumor-bearing mice (Youn JI et al., 2008; Ko JS et al., 
2009; Rodriguez PC et al., 2009; Fridlender ZG et al., 2009; Schmielau J et al., 
2001). This point is not simply an issue of semantics or nomenclature, but it is 
important to understand the biology of neutrophils and their role in pathological 
processes. 
Keeping this issue in mind, in addition to the co-expression of CD15 and CD66b, we 
try to further characterise neutrophils by the additional expression of molecules 
known to be present on their surface. 
Our results clearly demonstrated the presence of two subsets, CD15
+
CD66b
high
 and 
CD15
int
CD66b
int
, differentially expressed in the blood and in the lamina propria of 
patients with IBD, CRC and in healthy individuals. The CD15
+
CD66b
high
 population 
was enriched in intestinal tissues, while CD15
int
/CD66b
int
 cells represented the 
dominant circulating neutrophil population, especially in IBD and CRC patients.  
The CD15
+
CD66b
high
 population was characterized by a higher expression of 
HLADR and CXCR4 inside CRC tumors but not in the inflamed mucosa of IBD 
patients.  The vast majority of CD15
+
CD66b
high
 cells co-expressed HLA-DR and 
CD86 in the intestinal tissue as compared with the circulating population. While no 
differences were observed concerning the expression of the inhibitory molecule PD-
L1 among IBD and CRC patients, in healthy subjects a higher proportion of tissue-
associated CD15
+
CD66b
high
 cells expressed PD-L1. On the contrary, CD54, a 
molecule necessary for neutrophil transmigration through the endothelial monolayer, 
was expressed especially in IBD patients rather than in healthy individuals.  
Also the CD15
int
CD66b
int
 population expressed higher levels of HLA-DR in the 
lamina propria rather than in blood. These cells also expressed higher levels of CD1d 
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inside the tumors as compared with blood, and CXCR4 was more expressed by 
tissue-derived CD15
int
CD66b
int
 neutrophils. 
Similarly to CD15
+
CD66
high
 neutrophils, also CD15
int
CD66b
int 
showed an increased 
expression of CD54 in IBD patients as compared to the other subjects, especially in 
the blood. To note, a higher number of these circulating cells expressed also the L-
selectin, that facilitate the infiltration of neutrophils into the site of inflammation, and 
it was mostly expressed by cells isolated from IBD and CRC patients. 
The increased levels of antigen presenting molecules, of co-stimulatory molecules 
and of molecules involved in trafficking, suggest a possible role of these cells in 
antigen presentation in the gut. In a possible scenario, circulating neutrophils are 
recruited in the inflamed mucosa (of both IBD and CRC patients) by an alteration in 
the intestinal microflora, which has been clearly demonstrated for IBD and CRC 
patients (Liu Z et al., 2013). In the gut, then, these neutrophils might participate in the 
activation of other immune cells. 
Our results show that, especially inside CRC tumors, there is an increased frequency 
of CD15
+
CD66b
high
 cells co-expressing HLA-DR and CD86, both involved in the 
presentation of antigens to CD4+T cells, but also of CD1d, a molecule necessary for 
lipid antigen presentation to iNKT cells. The role of iNKT cells to participate in 
antitumor responses has been documented in multiple human and animal cancer 
studies (Berzofsky JA et al., 2009, Cerundolo V et al., 2009). Several tumor types 
have been shown to express CD1d, and tumor expression of CD1d has been directly 
correlated with the ability of iNKT cells to induce direct tumor cytolysis in vitro and 
promote iNKT-mediated tumor immunity in vivo (Haraguchi K et al., 2006; 
Renukaradhya GJ et al., 2008). Contradictory data on the expression of CD1d in IBD 
patients have been reported. Page et al. reported that the expression of CD1d is higher 
in the affected ileum and cecum of IBD patients (Page MJ et al., 2000). However, a 
more recent report suggested that, in contrast to surface epithelium in the normal 
colon, epithelial cells derived from IBD patients do not express CD1d (Perera L et al., 
2007). Neither study addressed CD1d expression on other cell types including 
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neutrophils, which could contribute to the activation of iNKT cells and the 
modulation of intestinal immune responses. Our results indicate that CD1d 
expression was very low on the surface of circulating and tissue-associated 
neutrophils isolated from IBD patients. On the contrary, HLA-DR was highly 
expressed on the surface of tissue-derived neutrophils isolated from the inflamed 
mucosa of IBD patients. As for CD1d, HLA-DR expressed by neutrophils may 
present antigens to CD4+T cells, thus are able to contributing to sustain the large 
amounts of T helper-derived pro-inflammatory cytokines observed in the lamina 
propria of IBD patients. In a murine colitis model induced by the adoptive transfer of 
CD4+ T cells PMN isolated from the inflamed colon expressed HLA-DR and CD86 
(Ostanin DV et al., 2012). In contrast with our results, these findings were not 
confirmed in other murine colitis models or in patients suffering from chronic 
intestinal diseases.  
We also observed that, inside CRC tumors, PD-L1 was scarcely expressed on human 
PMN subsets. Multiple solid tumor types including melanoma, RCC, NSCLC, 
thymoma and ovarian, express PD-L1 to generate an immunosuppressive tumor 
microenvironment and avoid T cell cytolysis (Blank C et al., 2007; Iwai Y et al., 
2002; Blank C et al., 2005). Although PD-L1 blockade produced successful results in 
patients with advanced melanoma and NSCLC (Brahmer JR et al., 2012; Hodi FS et 
al., 2010), preliminary studies on CRC patients revealed that CRC tumor cells, 
similarly to what we observed for CRC-derived neutrophils, manifest low expression 
of PD-L1, suggesting that CRC-derived cells may respond less to PD-1 or PD-L1 
inhibition (Taube JM et al., 2014).  
Our results also showed a downregulation of CD62L and an upregulation of CD54 
and CXCR4 expression on infiltrating CD15
+
CD66b
high
 neutrophils of CRC patients. 
These results were consistent with recent studies showing that Tumor associated 
neutrophils displayed a more activated phenotype (CD62L
low
CD54
high
) (Pignatti P et 
al., 2005; Fortunati E et al., 2009) as compared to circulating neutrophils and with the 
fact that CXCR4 is overexpressed in human cancers (Uhlen,& Rhim, 2010).  The 
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migration of leukocytes into inflamed bowel tissue is central to the pathogenesis of 
IBD. Under inflammatory conditions, a large number of activated immune cells 
infiltrate the intestinal mucosa. These immune cells, among them also neutrophils, 
express high levels of CD62L and CD54, which further induce intermolecular 
interactions of leukocytes in the blood circulation to migrate into the intestinal 
mucosa, and promote local inflammatory response (Baumgart DC  et al., 2012; 
Manichanh C et al., 2012; Ordás I et al., 2012; Latella G et al., 2012;Van Assche and 
Rutgeerts, 2005; Bernstein et al. 1998). This is confirmed by our results, that showed 
increased expression levels of CD54 on both PMN subsets infiltrating inflamed 
mucosa of IBD patients, and an increase of CD62L specifically on tissue-derived 
CD15
int
CD66b
int
  neutrophils. 
The patients that we had the possibility to analyse were all under different types of 
pharmacological treatments. We considered in our analysis the possibility that these 
drugs might modify i) the frequency of the neutrophils sobpopulation that we 
identified and ii) in general the expression of some or all the surface molecules 
expressed by these subpopulations. 
 
Since the pharmacological treatments were different, we grouped the patients for 
immunosuppressive therapy that they receiving or not at the time of surgical 
intervention. Immunosuppressants include thiopurines such as 6-mercaptopurine (6-
MP), azathioprine (AZA), methotrexate (MTX), and steroids and anti-TNF 
(infliximab or adalimumab). 6- Mercaptopurine (6-MP) and azatioprine (AZA) 
inhibit lymphocyte proliferation through the incorporation of active drug metabolites 
into cellular nucleotides, which likely results in anti-inflammatory effects and in 
suppression of T cell function and natural killer cell activity (Sahasranaman S et al., 
2008; Regueiro MD et al., 2000). These drugs also downregulate the levels of 
inhibitory molecules and molecules involved in trafficking, especially CD54 (Chang 
CZ et al., 2010). 
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Our results showed that immunosuppressants reduce the number of both circulating 
subsets of PMN in IBD and CRC patients, but upregulate the expression levels of 
antigen presenting molecules and co-stimulatory molecules. 
In IBD and CRC-derived tissues, immunosuppressants seemed to slightly increase the 
frequency of the CD15
+
CD66b
high
 subpopulation, while reducing the percentage of 
the intermediate subset. To note, especially in the CD15
+
CD66b
high
 population, 
immunosuppressants reduce the expression levels of antigen presenting molecules 
such as CD1d, of molecules involved in trafficking such as CD54 and CD62L in IBD 
and CRC patients. These data suggest that this population might be a direct target of 
the immunosuppressive therapy, underlying their potential contribution in the 
intestinal pathogenesis. 
Tumor-associated macrophages (TAMs) are an important component of the 
inﬂammatory inﬁltrate of several tumors (Mantovani et al., 1992) and are essential 
mediators of the relationship between inﬂammation and cancer. In the tumor 
microenvironment macrophages can express pro- or anti-tumoral functions. This 
plasticity reﬂects macrophages peculiarity to acquire distinct phenotypes in response 
to distinct microenvironmental signals (Sica and Mantovani, 2012). Relatively little is 
known about neutrophils in human cancers and IBD and if, in different inflammatory 
or tumor-associated environments, also neutrophils might acquire distinct 
phenotypes. Recent evidences suggest that tumor infiltrating neutrophils, termed 
TANs, undergo polarization toward distinct phenotypes in response to certain tumoral 
environmental signals (Fridlender et al., 2009). To date, two subsets of TANs with 
distinct phenotypes and properties have been characterized (Fridlender ZG et 
al.,2009; Piccard H et al., 2012). The majority of TANs in the tumor 
microenvironment exhibit an immunosuppressive and pro-tumorigenic phenotype, a 
subset termed N2 similarly to the macrophage counterpart M2.  
Melanoma patients also show a specialized subset of immunosuppressive neutrophils 
in their blood that is induced by serum amyloid A1 (SAA-1), produces the anti-
inflammatory cytokine IL-10 and promotes the interaction of these neutrophils with 
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invariant natural killer T cells that decreases their IL-10 production while enhancing 
IL-12, thereby dampening their immunosuppressive properties, again resulting in the 
existence of two distinct neutrophil populations with defined functions (De Santo C 
et al., 2000). The presence of TANs have been demonstrated to be associated with 
poor clinical outcomes of several malignancies including clear cell renal cell 
carcinoma (Jensen HK et al., 2009), gastric cancer (Zhao JJ et al., 2012),colorectal 
cancer (Rao HL et al., 2012), and hepatocellular carcinoma (Li YW et al., 2011).  
Recent studies showed that M1 macrophages, the “inflammatory” macrophage 
phenotype, displayed significantly higher CD86 and HLA-DR levels as compared to 
M2 (Buchacher T et al., 2015), while M2 macrophages expressed subset-specific 
markers include a scavenger receptor CD163, a galactose-type C-type lectin, CD301 
(Prokop S et al., 2011; Raes G et al., 2005), and a scavenger receptor expressed by 
both tolerogenic macrophages and dendritic cells, CD206 (Heusinkveld M et al., 
2001; Verreck FA). No unique cell-surface receptors have yet been identified for M1 
macrophages (Heusinkveld M et al., 2001; Verreck FA). 
We evaluated if circulating and tissue-infiltrating CD15
+
CD66b
high
 and 
CD15
int
CD66b
int
 neutrophils also showed N1/N2 phenotype in IBD, CRC patients 
and healthy individuals. 
Our results showed the co-expression of CD86 and HLA-DR on CD15
+
CD66b
high
, 
surface markers typical of an inflammatory M1/N1 phenotype. Nevertheless, we also 
observed a strong increase of the frequency of CD15
+
CD66b
high
 expressing CD163, 
CD301, CD206 and CD200R (typical M2/N2 markers) in the inflamed mucosa of 
IBD patients and inside the tumor. While we were expecting a skew towards an N2 
phenotype inside CRC tumors, we were surprised to find such a high proportion of 
neutrophils with an N2 phenotype in IBD patients.  
Although unexpected, these data were also confirmed by functional data.  When we 
characterized circulating neutrophils ex vivo, we found that the vast majority of cells 
secreted IL-10, a potent anti-inflammatory cytokine involved in N2 polarization, and 
CD15
+
CD66b
high
 neutrophils isolated from the inflamed mucosa of IBD patients 
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secreted low levels of IFN-γ. The published literature on the production of IL-10 by 
human neutrophils is conflicting. Despite the fact that several studies (Tsuda Y et al., 
2004, Mencacci A et al., 1996; Noel Gb et al., 2011; Tosello Boari J et al., 2012) 
have shown that mouse neutrophils produce IL-10 in response to a variety of 
infections, and the data are widely accepted, only two groups of investigators were 
able to reproduce those results using human neutrophils (De Santo C et al., 2010; 
Balderramas HA et al., 2014), but other study showed that human neutrophils did not 
secrete IL-10 in response to various inflammation-associated molecules (Mantovani 
A et al., 2011). 
Additional functional studies with a higher number of patients will be required to 
definitively support our findings. 
In the gut, bacteria play different important functions, and neutrophils are immune 
cells deputed to sense variations in the bacterial communities, for example during  
pathogens infections.  
To further functionally characterise ex vivo neutrophils isolated from IBD and CRC 
patients, and evaluate if they are endowed with distinct functional capacities, we 
stimulated them with different bacteria cues. 
 We encountered technical difficulties to perform in vitro experiments with freshly 
isolated neutrophils. Firstly, neutrophils are short lived and PMN isolated from the 
lamina propria of patients were highly stressed and died faster probably for the long 
time of tissue preparation. For these reasons when we used tissue-derived neutrophils 
to perform in vitro experiments, these cells did not respond.  
We therefore decided to perform experiments with circulating neutrophils, as 
previously published (Hayashi F et al., 2003). As shown for monocytes, neutrophils 
secrete IL-10  after LPS stimulation (Nizzoli G et al., 2016).  
The endogenous intestinal microflora plays a crucial role in the pathogenesis of IBD 
(Sartor RB et al., 2007; Shanahan F, 2012) and it has been shown that several 
bacteria produce toxins that disturb the cell cycle resulting in altered cell growth in 
cancer (Littman AJ et al., 2004; Koyi H et al., 2001; Kocazeybek B, 2003) but if 
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these stimuli had a direct impact on neutrophils activation is still largely unknown. 
We thus evaluated neutrophil responses to luminal and mucus-associated bacteria 
stimuli. Our results showed that under mucosal bacterial stimulation, neutrophils 
isolated from CRC patients secreted significant amounts of IL-10 but almost no 
IL12p70 while, in IBD patients, neutrophils activated by luminal bacteria, secreted 
IL12p70 and almost no IL-10. These data confirm that neutrophils functions are 
strongly influenced by exposure to intestinal bacteria and that these bacteria might 
directly participate in the skewing of the functional phenotype of neutrophils in IBD 
and CRC patients. 
Finally, as known in literature, the release of cytokines was only one of different 
mechanism adopted by neutrophils to respond to bacterial stimulation. Neutrophil 
effector functions also include production and release of reactive oxygen species 
(ROS). Evidences showed a ROS induction by neutrophils in response to microbial 
signals (Lambeth JD et al., 2004).  On these bases, evaluated ROS production under 
luminal and mucus-associated bacterial stimulation and we showed that circulating 
neutrophils of IBD patients seemed to react more intensely as compared with CRC 
patients and healthy individuals. 
In conclusion, by taking advantage of different surface markers, we identified two 
population of neutrophils differentially expressed in the peripheral blood and in the 
gut tissue of patients with IBD and CRC. These two subpopulation not only 
expressed different surface molecules associated to antigen presentation, activation, 
and trafficking of neutrophils in both peripheral blood and gut mucosa, but also 
demonstrated phenotypical and functional differences between these patients. These 
populations expressed molecules associated to N2 phenotype and secreted more IL-
10. Immunosuppressive therapy modulated their relative frequencies and the 
expression of specific surface molecules involved in their functional activities, 
suggesting an important role of neutrophils in the pathologies that we have studied.  
Finally, functional analyses revealed that these cells produce cytokines and ROS in 
response to the intestinal bacteria, especially mucus-associated bacteria.  
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Our results therefore suggested that the interaction between gut bacteria and 
neutrophils can contribute to the initiation and propagation of these intestinal 
pathologies and, in the future, the block of this interaction may be a potential 
therapeutic target in both IBD and CRC. 
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